var title_f16_41_17040="AC shear test";
var content_f16_41_17040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acromioclavicular shear test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exerting a shear force across the acromioclavicular (AC) joint often elicits pain in patients with AC disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17040=[""].join("\n");
var outline_f16_41_17040=null;
var title_f16_41_17041="Nasal embryology";
var content_f16_41_17041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal embryology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The developing nose in a 30-day-old embryo. Note the nasal pits (n) and primitive mouth (m).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17041=[""].join("\n");
var outline_f16_41_17041=null;
var title_f16_41_17042="SCCA left vest skin";
var content_f16_41_17042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    SCCA of the left vestibule with direct extension to the skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright &copy;1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17042=[""].join("\n");
var outline_f16_41_17042=null;
var title_f16_41_17043="Potassium acid phosphate: Drug information";
var content_f16_41_17043=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium acid phosphate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Phos&reg; Original",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Urinary Acidifying Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urine acidification:",
"     </b>",
"     Oral: 1000 mg dissolved in 6-8 oz of water 4 times/day with meals and at bedtime; for best results, soak tablets in water for 2-5 minutes, then stir and swallow",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Phos&reg; Original: 500 mg [scored; phosphorus 114 mg and potassium 144 mg (3.7 mEq) per tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acidifies urine and lowers urinary calcium concentration; reduces odor and rash caused by ammoniacal urine; increases the antibacterial activity of methenamine",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea, nausea, stomach pain, flatulence, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Local tissue necrosis with extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmia, dyspnea, edema, hyperphosphatemia, hypocalcemia, mental confusion, paralysis, paresthesia, tetany",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment; hyperkalemia, hyperphosphatemia; infected magnesium ammonium phosphate stones",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tissue breakdown: Use with caution in patients with severe tissue breakdown (eg, chemotherapy or hemodialysis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Potassium Acid Phosphate may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13891111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13891116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13891114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is excreted into breast milk (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (K-Phos Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $21.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, phosphorus, calcium; serum salicylates (if taking salicylates)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum phosphorus: Both low and high ends of the normal range are higher in children than in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 4.5-7.5 mg/dL (1.45-2.42 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: ~4-6 mg/dL (1.29-1.94 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2.5-4.5 mg/dL (0.81-1.45 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary pH: 4.6-8.0",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The principal intracellular cation; involved in transmission of nerve impulses, muscle contractions, enzyme activity, and glucose utilization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from upper GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9793 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17043=[""].join("\n");
var outline_f16_41_17043=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211607\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211618\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211610\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211611\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211597\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211582\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211598\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211616\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211601\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211586\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299912\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211591\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211593\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13891111\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13891116\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13891114\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211602\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422276\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211595\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203062\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211585\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211600\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17044="Carmustine lung fibrosis PA";
var content_f16_41_17044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of patient with late onset carmustine lung fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note hilar elevation and slight apical fibrosis but absence of obvious interstitial fibrotic changes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronan O'Driscoll, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17044=[""].join("\n");
var outline_f16_41_17044=null;
var title_f16_41_17045="Ibuprofen and diphenhydramine: Patient drug information";
var content_f16_41_17045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ibuprofen and diphenhydramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/63/30709?source=see_link\">",
"     see \"Ibuprofen and diphenhydramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12864215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg; PM Caplets [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; PM Liqui-Gels&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15235381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug right before or after heart bypass surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15235383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15235382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700954",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 12 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3974222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diphenhydramine, ibuprofen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3986302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you do not have time to get a full night&rsquo;s sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15235387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15235388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15235389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15235385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15235386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15235390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15235391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86870 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-1C172F50BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17045=[""].join("\n");
var outline_f16_41_17045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864215\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235381\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235383\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235382\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235387\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235388\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235389\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235385\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235386\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235390\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15235391\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/63/30709?source=related_link\">",
"      Ibuprofen and diphenhydramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17046="Red blood cell mechanics";
var content_f16_41_17046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Red blood cell mechanics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Mohandas Narla, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17046/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/41/17046/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During its passage through the circulation, an erythrocyte that is 7 to 8 microns in diameter must elongate, tank tread, and otherwise deform to pass through 3 micron diameter capillaries and 1 micron wide and 0.5 micron thick endothelial slits in the red pulp of the spleen (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ). Thus, during its 120-day life span, the erythrocyte must undergo extensive passive deformation and must be mechanically stable to resist fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell deformability is influenced by three distinct cellular components [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell shape or cell geometry, which determines the ratio of cell surface area to cell volume",
"      <span class=\"nowrap\">",
"       (SA/V);",
"      </span>",
"      higher values of",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      facilitate deformation.",
"     </li>",
"     <li>",
"      Cytoplasmic viscosity, which is primarily regulated by the mean corpuscular hemoglobin concentration (MCHC) and is therefore influenced by alterations in cell volume.",
"     </li>",
"     <li>",
"      Membrane deformability and mechanical stability, which are regulated by multiple membrane properties, which include elastic shear modulus, bending modulus, and yield stress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either directly or indirectly, membrane components and their organization play an important role in regulating each of the factors that influence cellular deformability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL SHAPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biconcave disc shape of the normal red cell (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ) creates an advantageous",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    relationship, allowing the red cell to undergo marked deformation while maintaining a constant surface area. The normal human adult red cell has a volume of 90 fL and a surface area of 140 &micro;2. If the red cell were a sphere of identical volume, it would have a surface area of only 98 &micro;2. Thus, the discoid shape provides approximately 40 &micro;2 of excess surface area, or an extra 43 percent, that allows the red cell to undergo extensive deformation.",
"   </p>",
"   <p>",
"    Most deformations occurring in vivo and in vitro involve no increase in surface area. This is important because the normal red cell can undergo large linear extensions of up to 230 percent of its original dimension while maintaining its surface area, but an increase of even 3 to 4 percent in surface area results in cell lysis.",
"   </p>",
"   <p>",
"    Because the acquisition and maintenance of a favorable",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    is crucial to red cell function, it is useful to understand how the red cell acquires its discoid shape. The immediate precursor of the mature discocytic red cell is the non-nucleated reticulocyte, which is produced when the normoblast extrudes its nucleus. In contrast to red cells, immature reticulocytes are multilobular and motile, contain mitochondria and ribosomes, and synthesize hemoglobin and certain membrane components, including band 3, GLUT1 and protein 4.1. The deformability of these reticulocytes is only about 10 percent that of discocytic red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both deformability and mechanical stability of reticulocytes improve during maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/5\">",
"     5",
"    </a>",
"    ]. In two to three days, motile reticulocytes evolve further in the bone marrow, first to become deep cup-shaped nonmotile cells that still contain ribosomes, and finally to mature fully hemoglobinized discocytic red blood cells lacking organelles. Major reorganizations of membrane phospholipids, skeletal proteins, and integral proteins accompany acquisition of the discoid shape and enhanced deformability. These include loss of membrane lipids, loss of integral proteins, such as transferrin receptors, insulin receptors, and fibronectin receptors, a major reorganization of the skeletal protein network, and a progressive loss of volume and cell water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H3#H3\">",
"     \"Macrocytosis\", section on 'Reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alterations in the SA/V ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having acquired the discoid shape, the mature red cell must maintain this favorable",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    relationship during its circulating life span. Either membrane loss, leading to a reduction in surface area, or an increase in cell water content, leading to an increase in cell volume, will create a more spherical shape with less redundant surface area. This loss of surface area redundancy results in reduced cellular deformability, compromised red cell function, and diminished survival. Increased osmotic fragility is a characteristic feature of all red cell populations with less than normal surface redundancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8132985\">",
"    <span class=\"h3\">",
"     Experimental manipulation of the SA/V ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of the",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    ratio for red cell survival was tested by incubating red cells in vitro with progressively increasing concentrations of lysophosphatidylcholine (LPC) in order to reduce their surface area at constant volume. The treated red cells were then perfused ex vivo into normal human spleens and the degree of splenic retention measured. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of red cells with progressively increasing concentrations of LPC resulted in progressively decreased",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio, increased sphericity, increased osmotic fragility, and decreased deformability.",
"     </li>",
"     <li>",
"      Splenic retention of treated red cells increased with increasing surface area loss and decreasing",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio. Whereas only 9 percent of untreated control red cells were retained by the spleen over a two-hour period, splenic uptake increased with progressive reductions in",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratios. A 13 percent reduction in",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio resulted in retention of 27 percent of red cells, while a reduction of 23 percent resulted in 92 percent of red cells being retained by the human spleen.",
"     </li>",
"     <li>",
"      Surface area-deficient red cells that had escaped repeated passages through the spleen appeared to undergo volume loss to compensate for their surface area loss. This reduction in volume could represent an adaptive mechanism by which surface area-deficient red cells increase their",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio to enable their subsequent transit through the spleen. Cell deformation-mediated increase in membrane cation permeability could account for such volume loss. This phenomenon could explain the decreased cell volume of senescent normal red cells and of hereditary spherocytic red cells with decreased surface area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8132978\">",
"    <span class=\"h3\">",
"     Clinical examples",
"    </span>",
"    &nbsp;&mdash;&nbsp;As examples, protein defects involving alpha- and beta-spectrin, ankyrin, band 3, or protein 4.1R lead to a loss of cohesion between the lipid bilayer and the spectrin-based membrane skeleton, resulting in membrane vesiculation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mechanically unstable membrane. Both of these processes lead to membrane fragmentation and the generation of cells with reduced surface area, as seen in congenital hemolytic anemias such as hereditary spherocytosis and hereditary elliptocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of the favorable",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    ratio is also seen in several other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial phagocytosis of the red cell by macrophages leads to reduced surface area and the generation of spherocytes in certain immune hemolytic anemias.",
"     </li>",
"     <li>",
"      In some forms of hereditary stomatocytosis, the membrane defect results in increased cell volume due to impaired volume regulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"       \"Stomatocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A different type of red cell abnormality occurs in other disorders in which the",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    ratio is",
"    <strong>",
"     increased",
"    </strong>",
"    above normal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with liver disease, increased membrane cholesterol content raises the cell surface area which, in the presence of normal cell volume, increases the degree of surface area redundancy. This excess surface area is manifested morphologically by a target or spur cell appearance and functionally by increased osmotic resistance (decreased osmotic fragility). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link\">",
"       \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In certain hemoglobinopathies (eg, thalassemia and hemoglobin CC), the same abnormality is induced by decreased cell volume in the face of normal membrane surface area. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"       \"Pathophysiology of beta thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CYTOPLASMIC VISCOSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoplasmic viscosity, another regulatory component of red cell deformability, is largely determined by the mean corpuscular hemoglobin concentration (MCHC), which is determined in part by cell water content [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/3\">",
"     3",
"    </a>",
"    ]. The lipid components and integral proteins of the red cell membrane involved in transport function play a crucial role in volume homeostasis of the red cell, maintaining the cell hemoglobin concentration at levels that do not unduly influence the ability of the cell to deform.",
"   </p>",
"   <p>",
"    As the hemoglobin concentration rises from 27 to 35",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (the normal range for RBC hemoglobin concentration or MCHC), the viscosity of hemoglobin solution increases from 5 to 15 centipoise (cP), 5 to 15 times that of water (",
"    <a class=\"graphic graphic_figure graphicRef82597 \" href=\"UTD.htm?33/42/34477\">",
"     figure 1",
"    </a>",
"    ). At these levels, the contribution of cytoplasmic viscosity to cellular deformability is negligible. However, viscosity increases exponentially at hemoglobin concentrations greater than 37",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    reaching 45 cP at 40",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    170 cP at 45",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and 650 cP at 50",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    At these levels, cytoplasmic viscosity may become the primary determinant of cellular deformability. Thus, cellular dehydration, usually due to the failure of normal volume homeostasis mechanisms, can severely impair cellular deformability and thus decrease optimal oxygen delivery by impairing the ability of red cells to undergo rapid deformation necessary for passage through the microvasculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in proteins involved in transport processes, acquired alterations in these proteins due to membrane oxidation, or other changes induced by mutant hemoglobin interacting with the membrane can lead to marked cellular dehydration. As examples, cellular dehydration reduces red cell deformability in hereditary xerocytosis, sickle cell anemia, hemoglobin CC, and beta thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=see_link\">",
"     \"Xerocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H17#H17\">",
"     \"Specific therapies for sickle cell disease\", section on 'Mechanism of erythrocyte dehydration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Red blood cell dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEMBRANE DEFORMABILITY AND STABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the red cell membrane has two important properties related to the passage of red cells through the circulation: deformability and mechanical stability:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The property of membrane deformability determines the extent of membrane deformation that can be induced by a defined level of applied force. The more deformable the membrane, the less force that is required for the cell to pass through the capillaries and other narrow openings, such as fenestrations in the splenic cords.",
"     </li>",
"     <li>",
"      The property of mechanical membrane stability is defined as the maximum extent of deformation that a membrane can undergo, beyond which it cannot completely recover its initial shape. This is the point at which the membrane fails. Normal membrane stability allows human red cells to circulate for 120 days without fragmenting, while decreased stability leads to cell fragmentation under normal circulating stresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of both biochemically perturbed membranes and membranes from particular disease states have shown that deformability and stability can change with no fixed relation to one another [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/1\">",
"     1",
"    </a>",
"    ]. This observation implies that these two properties are regulated by different skeletal proteins and their interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Membrane mechanical properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanical behavior of the red cell membrane is complex, and depends upon the magnitude and duration of applied stresses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/3,4,12-14\">",
"     3,4,12-14",
"    </a>",
"    ]. At small values of applied force for short duration, the red cell membrane behaves as a viscoelastic solid, since it is capable of undergoing large elastic extensions and completely recovers its initial shape. In the nondeformed state, spectrin molecules exist in a folded conformation. During reversible deformation, the change in geometric shape occurs at a constant surface area. This process is characterized by rearrangement of the skeletal network in which some spectrin molecules become uncoiled and extended, while others are more compressed and folded [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, when small forces are applied over a long period of time, or when large forces are applied for a shorter period, the membrane yields and is unable to recover its initial shape. Under these circumstances, the membrane exhibits permanent \"plastic\" deformation due to the inability of the skeletal network to recover its prestressed configuration. As will be described in the next section, failure of recovery may also be due to defects in the membrane itself.",
"   </p>",
"   <p>",
"    In addition to its contribution to the elastic behavior of the membrane, the membrane skeleton plays a crucial role in the regulation of membrane mechanical stability, particularly junctional complexes in the skeletal network, as will be outlined in the following section. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link&amp;anchor=H3#H3\">",
"     \"Red blood cell membrane dynamics and organization\", section on 'Structural organization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Failure of membrane deformability and stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations indicate that membrane deformability can be reduced by an increase in intermolecular or intramolecular associations of the skeletal proteins or by an increased association of integral membrane proteins such as band 3 with the skeletal network (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. While normal red cells completely recover their shape following repeated cycles of deformation in the circulation, pathologic red cells with weakened or abnormal junctions between skeletal proteins fail to recover their initial shape and undergo plastic deformation (",
"    <a class=\"graphic graphic_figure graphicRef61578 \" href=\"UTD.htm?12/48/13058\">",
"     figure 3",
"    </a>",
"    ). Although substantial changes in lipid composition of the membrane have little effect on membrane mechanical properties, small changes in individual protein components can profoundly alter membrane behavior.",
"   </p>",
"   <p>",
"    One type of membrane failure occurs with increasing degrees of deformation in which the membrane becomes more extended and some of the spectrin molecules attain their maximal linear extension. This point is the limit of reversible deformability. A continued application of force would require an increase in surface area and the breaking of junctional complexes; this occurs at the weakest of the lateral protein-protein associations (spectrin-spectrin junction or spectrin-actin-protein 4.1R junction), leading to loss of membrane stability and membrane fragmentation.",
"   </p>",
"   <p>",
"    As an example, decreased membrane mechanical stability in hereditary elliptocytosis is due to either weakened spectrin-spectrin association, resulting from mutations in either alpha- or beta-spectrin, or a weakened spectrin-actin-protein 4.1 junction due to mutations in protein 4.1 (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17046/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The generation of irreversibly sickled cells in sickle cell anemia is also the result of plastic deformation of the membrane due to skeletal protein reorganization during repeated cycles of sickling and unsickling in the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link&amp;anchor=H9#H9\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Pathophysiology of hemolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link&amp;anchor=H3#H3\">",
"     \"Red blood cell membrane dynamics and organization\", section on 'Structural organization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5557840\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During its passage through the circulation, the erythrocyte must undergo extensive passive deformation and must be mechanically stable to resist fragmentation. These functions are influenced by three distinct cellular components: cell shape (surface to volume ratio), cytoplasmic viscosity, and membrane properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5558360\">",
"    <span class=\"h2\">",
"     Decreased SA/V ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membrane loss or increased cell volume create a more spherical shape, resulting in reduced cellular deformability, compromised red cell function, increased osmotic fragility, and diminished survival. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited membrane protein defects lead to a loss of cohesion between the lipid bilayer and the membrane skeleton or decreased membrane mechanical stability, generating cells with reduced surface area. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"       \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link\">",
"       \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial phagocytosis of antibody-coated red cells by macrophages leads to reduced surface area and the generation of spherocytes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Immunoadherence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some forms of hereditary stomatocytosis, the membrane defect results in increased cell volume due to impaired volume regulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"       \"Stomatocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5558367\">",
"    <span class=\"h2\">",
"     Increased SA/V ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    ratio is seen in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with liver disease, increased membrane cholesterol content raises the cell surface area, manifested by a target or spur cell appearance with decreased osmotic fragility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link\">",
"       \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In thalassemia and hemoglobin CC disease, an increased",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio is induced by decreased cell volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"       \"Pathophysiology of beta thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5558190\">",
"    <span class=\"h2\">",
"     Increased cytoplasmic viscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoplasmic viscosity is largely determined by the mean corpuscular hemoglobin concentration (MCHC), which is determined in part by cell water content. At MCHC levels greater than 37",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    cytoplasmic viscosity may become the primary determinant of cellular deformability. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Cytoplasmic viscosity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Examples include hereditary xerocytosis, sickle cell anemia, hemoglobin CC, and beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=see_link\">",
"     \"Xerocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H17#H17\">",
"     \"Specific therapies for sickle cell disease\", section on 'Mechanism of erythrocyte dehydration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Red blood cell dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5558334\">",
"    <span class=\"h2\">",
"     Red cell membrane properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red cell membrane has two important properties related to the passage of red cells through the circulation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Membrane deformability and stability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Membrane deformability determines the extent of membrane deformation that can be induced by a defined level of applied force.",
"     </li>",
"     <li>",
"      Mechanical membrane stability is the extent of deformation that a membrane can undergo, beyond which it cannot completely recover its initial shape.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, the generation of irreversibly sickled cells in sickle cell anemia is also the result of plastic deformation of the membrane due to skeletal protein reorganization during repeated cycles of sickling and unsickling in the circulation.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/1\">",
"      Chasis JA, Mohandas N. Erythrocyte membrane deformability and stability: two distinct membrane properties that are independently regulated by skeletal protein associations. J Cell Biol 1986; 103:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/2\">",
"      Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood 2008; 112:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/3\">",
"      Mohandas N, Chasis JA. Red blood cell deformability, membrane material properties and shape: regulation by transmembrane, skeletal and cytosolic proteins and lipids. Semin Hematol 1993; 30:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/4\">",
"      Mohandas N, Evans E. Mechanical properties of the red cell membrane in relation to molecular structure and genetic defects. Annu Rev Biophys Biomol Struct 1994; 23:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/5\">",
"      Chasis JA, Prenant M, Leung A, Mohandas N. Membrane assembly and remodeling during reticulocyte maturation. Blood 1989; 74:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/6\">",
"      Liu J, Guo X, Mohandas N, et al. Membrane remodeling during reticulocyte maturation. Blood 2010; 115:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/7\">",
"      Safeukui I, Buffet PA, Deplaine G, et al. Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen. Blood 2012; 120:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/8\">",
"      Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/9\">",
"      Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/10\">",
"      Clark MR, Mohandas N, Caggiano V, Shohet SB. Effects of abnormal cation transport on deformability of desiccytes. J Supramol Struct 1978; 8:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/11\">",
"      Mohandas N, Phillips WM, Bessis M. Red blood cell deformability and hemolytic anemias. Semin Hematol 1979; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/12\">",
"      Evans EA, La Celle PL. Intrinsic material properties of the erythrocyte membrane indicated by mechanical analysis of deformation. Blood 1975; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/13\">",
"      Hochmuth RM, Waugh RE. Erythrocyte membrane elasticity and viscosity. Annu Rev Physiol 1987; 49:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17046/abstract/14\">",
"      Discher DE, Winardi R, Schischmanoff PO, et al. Mechanochemistry of protein 4.1's spectrin-actin-binding domain: ternary complex interactions, membrane binding, network integration, structural strengthening. J Cell Biol 1995; 130:897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7092 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17046=[""].join("\n");
var outline_f16_41_17046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5557840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL SHAPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alterations in the SA/V ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8132985\">",
"      - Experimental manipulation of the SA/V ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8132978\">",
"      - Clinical examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CYTOPLASMIC VISCOSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEMBRANE DEFORMABILITY AND STABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Membrane mechanical properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Failure of membrane deformability and stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5557840\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5558360\">",
"      Decreased SA/V ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5558367\">",
"      Increased SA/V ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5558190\">",
"      Increased cytoplasmic viscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5558334\">",
"      Red cell membrane properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7092|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/42/34477\" title=\"figure 1\">",
"      Hemoglobin and viscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/7/9334\" title=\"figure 2\">",
"      RBC membrane model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/48/13058\" title=\"figure 3\">",
"      Role of band 3 protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7092|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/59/26544\" title=\"picture 1\">",
"      Red cells in the spleen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17047="Risedronate: Drug information";
var content_f16_41_17047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Risedronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/5/41045?source=see_link\">",
"    see \"Risedronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10911785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actonel&reg;;",
"     </li>",
"     <li>",
"      Atelvia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actonel&reg;;",
"     </li>",
"     <li>",
"      Actonel&reg; DR;",
"     </li>",
"     <li>",
"      Apo-Risedronate&reg;;",
"     </li>",
"     <li>",
"      Dom-Risedronate;",
"     </li>",
"     <li>",
"      Novo-Risedronate;",
"     </li>",
"     <li>",
"      PMS-Risedronate;",
"     </li>",
"     <li>",
"      ratio-Risedronate;",
"     </li>",
"     <li>",
"      Riva-Risedronate;",
"     </li>",
"     <li>",
"      Sandoz-Risedronate;",
"     </li>",
"     <li>",
"      Teva-Risedronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paget's disease of bone:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     30 mg once daily for 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For retreatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than one course of retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis (postmenopausal):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Prevention and treatment: 5 mg once daily",
"     <b>",
"      or",
"     </b>",
"     35 mg once weekly",
"     <b>",
"      or",
"     </b>",
"     150 mg once a month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Delayed release tablet:",
"     </i>",
"     Treatment: 35 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis (males) treatment:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     35 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis (glucocorticoid-induced) prevention and treatment:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F218588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9565124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No studies performed in hepatic impairment; no dosage adjustment necessary due to lack of hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actonel&reg;: 5 mg, 30 mg, 35 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atelvia&trade;: 35 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Actonel&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241447.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241447.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Atelvia&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241450.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241450.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Avoid administration of oral calcium supplements, antacids, magnesium supplements/laxatives, and iron preparations within 30 minutes of risedronate administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet: Risedronate immediate release tablets must be taken on an empty stomach with a full glass (6-8 oz) of",
"     <b>",
"      plain water",
"     </b>",
"     (not mineral water) at least 30 minutes before any food, drink, or other medications orally to avoid interference with absorption. Patient must remain sitting upright or standing for at least 30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delayed release tablet: Risedronate delayed release tablets must be taken with at least 4 oz of",
"     <b>",
"      plain water",
"     </b>",
"     (not mineral water) immediately after breakfast. Patient must remain sitting upright or standing for at least 30 minutes after taking (to reduce esophageal irritation). Tablet should be swallowed whole; do not cut, split, crush, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Actonel&reg;: Treatment of Paget's disease of the bone; treatment and prevention of glucocorticoid-induced osteoporosis; treatment and prevention of osteoporosis in postmenopausal  women; treatment of osteoporosis in men",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atelvia&trade;: Treatment of osteoporosis in postmenopausal women",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6049623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Actonel&reg; may be confused with Actos&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Risedronate may be confused with alendronate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency may vary with product, dose, and indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum PTH levels increased (transient; &lt;30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 20%), nausea (4% to 13%), constipation (3% to 13%), abdominal pain (2% to 12%), dyspepsia (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (7% to 33%), back pain (6% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (8%), chest pain (5% to 7%), arrhythmia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (7%), dizziness (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (&le;5%), hypophosphatemia (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (2% to 5%), gastritis (3%), duodenitis (&le;1%), glossitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prostatic hyperplasia (5%; benign), nephrolithiasis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Joint disorder (7%), myalgia (2% to 7%), neck pain (5%), muscle spasm (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (3% to 10%), pharyngitis (6%), rhinitis (6%), dyspnea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (10%), acute phase reaction (&le;8%; includes fever, influenza-like illness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Diaphyseal femur fracture, dysphagia, esophageal cancer, esophageal ulcer, esophagitis, gastric ulcer, hypersensitivity reaction, musculoskeletal pain (rarely severe or incapacitating), osteonecrosis (primarily of the jaw), subtrochanteric femur fracture",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to risedronate, bisphosphonates, or any component of the formulation; hypocalcemia; inability to stand or sit upright for at least 30 minutes; abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3-5 years) therapy may be at an increased risk.  Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Dysphagia, esophagitis, esophageal or gastric ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue if new or worsening symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving  bisphosphonates. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, with concomitant chemotherapy or corticosteroids; poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer&rsquo;s labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ. However, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucocorticoid-induced osteoporosis: Evaluate sex steroid hormonal status prior to treatment initiation; consider appropriate hormone replacement if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Before initiation of therapy hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake, especially for patients with Paget's disease in whom the pretreatment rate of bone turnover may be greatly elevated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (not recommended in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not approved for use in pediatric patients with osteogenesis imperfecta due to lack of efficacy in reducing the risk of fracture.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food reduces absorption (similar to other bisphosphonates); mean oral bioavailability is decreased when given with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and nonteratogenic embryo/fetal effects have been reported in animal studies. There are no adequate and well-controlled studies in pregnant women. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F218566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends discontinuing nursing or discontinuing risedronate.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake. Take immediate release tablet with at least 6 oz of",
"     <b>",
"      plain water",
"     </b>",
"     (not mineral water) &ge;30 minutes before the first food or drink of the day other than water. Take delayed release tablet with at least 4 ounces of",
"     <b>",
"      plain water",
"     </b>",
"     immediately",
"     <b>",
"      after",
"     </b>",
"     breakfast.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Atelvia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (4): $157.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Actonel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $169.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $1183.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (4): $157.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $170.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Osteoporosis: Bone mineral density as measured by central dual-energy x-ray absorptiometry (DXA) of the hip or spine prior to initiation of therapy and at least every 2 years thereafter (6-12 months post-baseline if combined glucocorticoid and risedronate treatment, then every 2 years thereafter); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; consider measuring biochemical markers of bone turnover",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Paget&rsquo;s disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actonel (AR, AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CN, CO, CR, CZ, DE, DO, EC, EE, ES, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, JP, KP, MX, MY, NI, NL, PA, PE, PH, PL, PR, PT, PY, SG, SR, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Actonel Once A Month (IL);",
"     </li>",
"     <li>",
"      Actonel Once A Week (IL, ZA);",
"     </li>",
"     <li>",
"      Actoril (KP);",
"     </li>",
"     <li>",
"      Avestra (SE);",
"     </li>",
"     <li>",
"      Droriate (PK);",
"     </li>",
"     <li>",
"      Gusong (CL);",
"     </li>",
"     <li>",
"      Kantonel (KP);",
"     </li>",
"     <li>",
"      Optinate (DK, FI, KP, NO, SE);",
"     </li>",
"     <li>",
"      Osteoclax (CO);",
"     </li>",
"     <li>",
"      Osteonate OD (ID);",
"     </li>",
"     <li>",
"      Retonel (ID);",
"     </li>",
"     <li>",
"      Ribastamin (AR);",
"     </li>",
"     <li>",
"      Ribone (IL);",
"     </li>",
"     <li>",
"      Ridroqueen (KP);",
"     </li>",
"     <li>",
"      Riseto (KP);",
"     </li>",
"     <li>",
"      Risnel (KP);",
"     </li>",
"     <li>",
"      Risofos (IN);",
"     </li>",
"     <li>",
"      Risonato (EC);",
"     </li>",
"     <li>",
"      Ristonat (ID);",
"     </li>",
"     <li>",
"      Valetta (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: May require weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 13.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~24%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Poor, ~0.54% to 0.75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Initial: 1.5 hours; Terminal: 480-561 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (up to 85%); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Author Unknown, &ldquo;Safety Update: Bone-Building Drugs: Risks Explained,,&rdquo;",
"      <i>",
"       Consum Rep Health",
"      </i>",
"      , 2006, 18(5):3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards BJ, Hellstein JW, Jacobsen PL, et al, \"Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2008, 139(12):1674-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/19047674/pubmed\" id=\"19047674\" target=\"_blank\">",
"        19047674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filleul O, Crompot E, and Saussez S, \"Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,\"",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 2010, 136(8):1117-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/20508948/pubmed\" id=\"20508948\" target=\"_blank\">",
"        20508948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2003, 49:1281-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/14594094/pubmed\" id=\"14594094\" target=\"_blank\">",
"        14594094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2010, 68(2):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/19772941/pubmed\" id=\"19772941\" target=\"_blank\">",
"        19772941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2010, 17(1):25-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/20061894/pubmed\" id=\"20061894\" target=\"_blank\">",
"        20061894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2005, 63(11):1567-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/16243172/pubmed\" id=\"16243172\" target=\"_blank\">",
"        16243172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2007, 65(3):415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/17307586/pubmed\" id=\"17307586\" target=\"_blank\">",
"        17307586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo;",
"      <i>",
"       Bone",
"      </i>",
"      , 2008, 43(5):819-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/18672105/pubmed\" id=\"18672105\" target=\"_blank\">",
"        18672105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(13):1480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/20924014/pubmed\" id=\"20924014\" target=\"_blank\">",
"        20924014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(11):2267-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/20842676/pubmed\" id=\"20842676\" target=\"_blank\">",
"        20842676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(6):593-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/16899779/pubmed\" id=\"16899779\" target=\"_blank\">",
"        16899779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/41/17047/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10242 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-BCE9E00093-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17047=[""].join("\n");
var outline_f16_41_17047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10911785\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218582\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218583\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218606\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218586\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218587\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218588\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9565124\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218556\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218541\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441520\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218559\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218558\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6049623\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218604\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218562\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218545\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300007\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218550\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218578\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218552\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218565\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218592\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218566\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218567\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218564\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218554\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218568\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218544\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218561\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/5/41045?source=related_link\">",
"      Risedronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17048="Determinants of neutrophil movement";
var content_f16_41_17048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Determinants of neutrophil movement",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17048/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17048/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/41/17048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymorphonuclear or segmented neutrophil is the last stage of full maturation of the granulocyte. The mature neutrophil is of uniform size, and the nucleus is segmented into two to five lobes connected by thin chromatin strands.",
"   </p>",
"   <p>",
"    Neutrophils act as the first line of host cellular defense against bacterial infection and are important cellular constituents of acute inflammation, independent of etiology. This may occur either in tissues or across mucosal surfaces, thereby requiring the migration of neutrophils from the vasculature to areas of infection and inflammation. This process is very tightly regulated.",
"   </p>",
"   <p>",
"    The determinants of neutrophil movement are discussed here. A review of additional neutrophil functions, such as phagocytosis and microbe killing, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUTROPHIL AND ENDOTHELIAL CELL INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation is characterized histologically by the accumulation of leukocytes at the inflamed site due to the directional migration of circulating leukocytes. Migration out of the vasculature is first initiated by contact between the leukocyte and the inflamed vascular endothelium. Both the vascular endothelium and the leukocytes actively mediate this adhesive interaction.",
"   </p>",
"   <p>",
"    The molecular basis for leukocyte-endothelial cell adhesion has been explored in great detail during the past several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. It is now known that both leukocytes and endothelial cells express a variety of surface adhesion molecules that help mediate trafficking. The steps involved in leukocyte accumulation at an inflamed or infected site can be characterized as follows (",
"    <a class=\"graphic graphic_table graphicRef71824 \" href=\"UTD.htm?13/15/13564\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Margination",
"     </li>",
"     <li>",
"      Tethering",
"     </li>",
"     <li>",
"      Rolling",
"     </li>",
"     <li>",
"      Activation and tight adhesion",
"     </li>",
"     <li>",
"      Intraluminal crawling (locomotion)",
"     </li>",
"     <li>",
"      Transendothelial cell migration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Margination and tethering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils are subjected to strong shear forces as blood flows through the arterial circulatory system at high velocity. When viewing the microcirculation with the cine microscope, the vast majority of cells, including red cells, appear as an indistinguishable blur. But within this rapid flow, a subset of neutrophils is noted to tumble along the periphery of the blood vessel at a velocity about 100 times slower than the main flow, the result of loose selectin-mediated PMN interactions with the endothelial lining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rolling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under regular conditions, neutrophils move freely in plasma as blood courses over endothelial surfaces. With infection or inflammation, the induction of cytokines, such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNFa), or interferon gamma (INFg), causes endothelial cells to express E-selectin and to release interleukin-8 (IL-8), granulocyte macrophage colony-stimulating factor (GM-CSF), and platelet-activating factor (PAF) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The presence of these substances causes neutrophils to roll on activated endothelium via the loose binding of sialyl-Lewis-X (SleX) and L-selectin on neutrophil surfaces to E-selectin on endothelial cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the further release of inflammatory cytokines (from endothelial cells)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoattractants (from endothelium and extravascular sources), chemotactic receptors on neutrophils are activated; this increases the cell-surface expression of and stimulates the CD18 beta-2 integrins (Mac-1 and LFA-1), and also reduces the expression on neutrophils of L-selectin and SleX. As a result, neutrophils no longer roll; instead, they become firmly attached and flatten via the binding of beta 2 integrins to intercellular adhesion molecule-1 (ICAM-1) on activated endothelial cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2720278\">",
"    <span class=\"h2\">",
"     Intraluminal crawling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial firm adhesion to endothelium is dependent on LFA-1. However, once firm attachment occurs, neutrophils crawl along the lumen of the vessel. This seems to be mediated though Mac-1 adhesion and guided by gradients of chemoattractants that concentrate at endothelial junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/6\">",
"     6",
"    </a>",
"    ]. Interestingly, there appear to be mechanical receptors in the neutrophils that alter migration. In the presence of shear stress as occurs in flowing blood, neutrophils prefer to migrate perpendicular to the direction of shear, a property that seems to be mediated by Vav-1, a",
"    <span class=\"nowrap\">",
"     Rho/Rac",
"    </span>",
"    guanine nucleotide exchange factor that plays a central role in localizing beta-2 integrins. Neutrophils attach to inflamed endothelium and then crawl prior to transmigration, suggesting that crawling is a mechanism for finding the optimum site for transmigration. The adhesion receptors LFA-1, Mac-1, ICAM-1, and ICAM-2 appear to be critical for crawling on endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transmigration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils subsequently migrate out of the vasculature by squeezing between endothelial cells via integrin attachments and adherence to PECAM-1, a protein constitutively found at endothelial cell margins (and expressed on neutrophils) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The importance of integrins in mediating transendothelial migration is suggested by the finding that neutrophils isolated from CD18-deficient patients adhere to IL-1 stimulated endothelium but fail to transmigrate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutrophil migration across subendothelial basement membranes is dependent upon the degradation of membrane constituents by proteinases released from neutrophil granules [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/12\">",
"     12",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inhibition of gelatinase B, a metalloproteinase found in neutrophils which is capable of degrading type IV collagen, constrains neutrophil transbasement membrane migration but does not affect chemotaxis or degranulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inhibition of neutrophil elastase, which activates a preform of gelatinase B, also blocks transbasement membrane migration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extravascular migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migration of neutrophils across the extracellular matrix also depends upon the function of specific integrins. The surface expression of VLA-2 (Very late antigen-2), an integrin not detected on plasma PMNs, is essential for neutrophil locomotion in extravascular tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transepithelial migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The migration of neutrophils across",
"    <strong>",
"     epithelial",
"    </strong>",
"    cells is the basic definition of mucosal inflammation. As with transendothelial migration, transepithelial migration requires the continued expression of",
"    <span class=\"nowrap\">",
"     CD11b/CD18",
"    </span>",
"    on neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional molecules are required for this process. In particular, cells fail to migrate if neutrophils and epithelial cells do not express the integral membrane glycoprotein CD47, a 60 kD glycoprotein which is up-regulated on epithelial surfaces by INFg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEUTROPHIL MOVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In response to the binding of chemoattractants, neutrophils change their shape and crawl by alternating the extrusion and retraction of a frontal lamellipodia, a process that determines the direction of locomotion. These cells migrate in the direction of higher chemoattractant concentrations via a tractor-like motion as the lamellipodia fills with cytosol; this protrusion subsequently contracts by adhering briefly to the substrate, thereby providing the friction required for movement. The body of the neutrophil extends and elongates in the axis defined by the lamellar protrusion; this creates a tapered cell with a knobby tail [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The accuracy of orientation is exquisitely regulated since the cell can detect a 2 percent change in chemoattractant concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils move at speeds up to 30 micrometers per minute, thereby qualifying as the fastest cell in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/21\">",
"     21",
"    </a>",
"    ]. Their cell velocity oscillates between 10 and 30 micrometers per minute with a periodicity of 50 to 55 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/17,22\">",
"     17,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Molecular machinery of movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular underpinnings of neutrophil crawling have been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/6,21,23\">",
"     6,21,23",
"    </a>",
"    ]. Neutrophil activation induces contraction of the actin filamentous network (f actin) in the cytoplasmic cortical gel structure, presumably by inducing the phosphorylation of myosin via a transient increase in cytosolic calcium. Since the cortex is weakly cross-linked [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/24\">",
"     24",
"    </a>",
"    ], hydrostatic forces imposed by f actin contraction forces the membrane bilayer outwards at a region where it becomes detached from the underlying f actin network [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. At the site of membrane expansion, actin filaments assemble from monomeric subunits into relatively short (one micrometer) linear filaments. These filaments are cross-linked by actin binding protein, fimbrin, villin, fascin, and alpha actinin into a three-dimensional uniform network [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This cohesive network of actin filaments modulates the flow of cytosol, provides strength to the forming protrusion, anchors adhesion molecules, and welds the protrusion to the underlying substrate (",
"    <a class=\"graphic graphic_table graphicRef71824 \" href=\"UTD.htm?13/15/13564\">",
"     table 1",
"    </a>",
"    ). If actin binding protein expression is lost, the cell becomes immobile and responds feebly to chemoattractants by forming temporary blow-outs or blebs.",
"   </p>",
"   <p>",
"    To repeat this cycle, actin filaments must be rapidly disassembled [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/25\">",
"     25",
"    </a>",
"    ]. Gelsolin, which is activated at micromolar calcium concentrations, quickly severs actin filaments and blocks actin reassembly by capping actin barbed ends. The barbed ends of actin filaments serve as the nidus onto which actin subunits are added. Another highly conserved capping protein, CapZ, may also cap barbed ends, thereby preventing actin filament elongation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/27\">",
"     27",
"    </a>",
"    ]. Another filamentous actin binding protein, leufactin, may also underlie disassembly as its overexpression results in immobile cells and serious infection due to actin dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The next cycle cannot be initiated until these actin filaments are uncapped. Dissociation and uncapping of the Gelsolin-actin and profilin-actin complexes are mediated by polyphosphoinositides generated during signal transduction, which occurs with neutrophil activation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/26,30,31\">",
"     26,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signal transduction unifies neutrophil membrane activation with actin assembly or disassembly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/4,21,26,32\">",
"     4,21,26,32",
"    </a>",
"    ]. During cell stimulation, signal transduction cascades lead to either membrane breakdown or the synthesis of polyphosphoinositides:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membrane breakdown generates phosphoinositol and releases intracellular calcium and protons, thereby promoting actin disassembly.",
"     </li>",
"     <li>",
"      By comparison, polyphosphoinositide synthesis provides clusters of polyphosphoinositides promoting actin assembly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another important link between selective receptor mediated responses and changes in the actin cytoskeleton appears to be the myristoylated (MARCKS) protein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]; this molecule is a major specific substrate of protein kinase C that is phosphorylated during receptor mediated activation. MARCKS is thought to regulate the cross-bridge between actin and the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chemotaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotaxis is the directed movement of neutrophils in response to small peptide or lipid attractants released at sites of infection or inflammation. Guided by specific cell-surface receptors, neutrophils migrate toward higher concentrations of these molecules and stop at their source. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link&amp;anchor=H22#H22\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\", section on 'Neutrophil chemotaxis testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chemoattractants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of small peptide and lipid chemoattractants are generated in vivo either by host cells or infecting organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial-derived oligopeptides, such as formyl-methionyl-leucyl-phenylalanine (FMLP), serve as potent chemotaxins.",
"     </li>",
"     <li>",
"      Activation of the complement system leads to the generation of the potent chemotactic peptide C5a.",
"     </li>",
"     <li>",
"      Chemokines are small proteins of 70 to 80 amino acids with four conserved cysteines that form two essential disulphide bonds, a short amino-terminal and a relatively long carboxyl-terminal domain. Chemokines specific for neutrophils, called CXC chemokines, are distinguished from other chemokines by a protein motif consisting of the separation of the first two cysteines by one amino acid. By comparison, CC chemokines, which stimulate monocytes, basophils, eosinophils, and T cells but not neutrophils, have the first two cysteines adjacent to each other.",
"      <br/>",
"      <br/>",
"      CXC chemokines are produced by many different cell types; these include endothelial cells, platelets, neutrophils, T lymphocytes, and monocytes. They include interleukin-8 (IL-8) (previously known as neutrophil activating peptide 1), neutrophil activating peptide-2 (NAP-2), and GRO-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/37-42\">",
"       37-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelet activating factor (PAF) and leukotriene B4 are phospholipid chemoattractants that are derived from endothelial cells in response to inflammatory mediators.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotactic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils sense the presence of a chemoattractant when it binds its specific cell-surface receptor, which are either up regulated in response to cell activation or are constitutively expressed. Many different chemoattractant receptors may be found on the surface of neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     FMLP receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first chemoattractant receptors demonstrated on neutrophils were the N-formyl-tripeptide receptors, the most active being the f-Met-Leu-Phe (FMLP) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/43\">",
"     43",
"    </a>",
"    ]. As with all chemoattractant receptors found on neutrophils, the FMLP receptor demonstrates time-dependent saturable binding kinetics and a high affinity dissociation constant (Kd) (defined as the concentration required to bind 50 percent of available receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/44\">",
"     44",
"    </a>",
"    ]) for the specific chemoattractant. Studies using intact human neutrophils reveal the presence of approximately 50,000 FMLP receptors per cell with a Kd of 20nM [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. The FMLP receptor, which has been cloned [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], is stored in specific granules and vesicles.",
"   </p>",
"   <p>",
"    Streptococcus pneumonia is the most common bacterial pneumonia in humans. Prevention of systemic spread and sepsis requires the coordinated activation of CD38 found on most hematopoietic cells, including neutrophils. S. pneumonia releases formylated peptides in the lung which in turn bind to the FMLP receptor on neutrophils. This binding activates CD38, catalyzing the transformation of NAD+ to the active second messenger cADPR (cyclic ADP-ribose) thereby providing to the neutrophil a sustained influx of extracellular Ca++ for efficient neutrophil movement to the site of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     C5a receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils have approximately 50,000 to 100,000 receptors per cell for the chemotactic cleavage product from the fifth component of complement, C5a [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/49\">",
"     49",
"    </a>",
"    ]. The C5a receptor, which has been cloned, has a Kd of 2nM. Oocytes injected with C5a mRNA transcripts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/46,50\">",
"     46,50",
"    </a>",
"    ] result in oocytes with fully responsive transmembrane currents and calcium fluxes inhibitable by pertussis toxin, thereby indicating close coupling of the receptor with G-proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Chemokine receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils express high numbers of IL-8 receptors of two types, one highly specific for IL-8 (IL-8R1) and the other highly specific for IL-8 as well as other CXC chemokines (IL-8R2) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. There are approximately 20,000 IL-8R1, and 60,000 to 90,000 IL-8R2 molecules per neutrophil [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/54\">",
"     54",
"    </a>",
"    ]. IL-8R1 has a Kd of 0.8 nM for IL-8 and a Kd of 30 nM for GRO alpha and NAP-2, while IL-8R2 has mean Kds of 0.3 and 0.7 nM for GRO-alpha and NAP-2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cloning of the two IL-8 receptors indicates that their transmembrane architecture, which consists of seven hydrophobic transmembrane domains, is similar to all other chemotactic receptors found on neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/53,56\">",
"     53,56",
"    </a>",
"    ]. The seven transmembrane domain receptor family also includes receptors involved in signal transduction for vision, olfaction, hormone action, cell proliferation, and neurotransmission.",
"   </p>",
"   <p>",
"    In neutrophils, the seven hydrophobic transmembrane helices of these receptors are composed of 20 to 25 amino acids separated by three hydrophilic loops exposed at the cytosolic and the extracellular face of the plasma membrane. A conserved disulfide bridge stabilizes the first and second extracellular loop (",
"    <a class=\"graphic graphic_figure graphicRef78149 \" href=\"UTD.htm?18/63/19445\">",
"     figure 1",
"    </a>",
"    ). The transmembrane domains have several conserved amino acids which form the agonist-binding pocket. The conserved amino acids in the intracellular domains confer a common conformation, thereby ensuring their interaction with Gi2-proteins. The diversity of amino acid structure of the extracellular and transmembrane domains confers ligand specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All CXC chemokines require the amino terminal sequence Glu4-Leu5-Arg6 (ELR) for receptor recognition and signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/58\">",
"     58",
"    </a>",
"    ]. A two-site model for receptor activation and for selectivity between CXC and CC chemokines has been proposed with the initial receptor contact provided by the main body of the chemokine and the activation provided by the amino terminal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/59\">",
"     59",
"    </a>",
"    ]. However, this model does not appear to extend to complement receptors, as the C5a receptor activation site is located in the C-terminal region whereas the N-terminal region is involved in receptor binding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Lipid chemoattractant receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils also have receptors to secreted products of phospholipid oxidation and oxygenation released from endothelial cells, macrophages, neutrophils, as well as from bacterial toxins and oxidants. Platelet-activating factor (PAF) is 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine formed in endothelial cells in response to stimulation of specific receptors for thrombin, bradykinin, histamine, ATP, and angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of radiolabeled PAF to neutrophils reveals 1000 high affinity (Kd of 0.2 nM) and 270,000 low affinity (Kd of 500 nM) sites per cell, respectively. As with other neutrophil chemoattractant receptors, the PAF receptor consists of seven membrane spanning domains and belongs to the family of Gi2 protein coupled receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. It is activated by short sn-2 residues present in PAF and other diacylphosphatidylcholines containing sn-2 polyunsaturated fatty acyl residues vulnerable to oxidative fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/68\">",
"     68",
"    </a>",
"    ]. Among the chemoattractants, PAF is unique in inducing lipid rich cytoplasmic inclusions which primes neutrophils for enhanced LTB4 release [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukotriene B4 (LTB4) is formed from arachidonic acid in the lipoxygenase-catalyzed reaction by oxygenation at C-5 followed by further transformation to Leukotriene A4. This unstable epoxide intermediate is converted to LTB4 by hydrolysis. Eicosatetraenoates (ETEs), 5-oxo-15(OH)-ETE, share structural motifs, synthetic origins, and bioactions with LTB4 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17048/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27128793\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils act as the first line of host cellular defense against bacterial infection and are important cellular constituents of acute inflammation. These tightly regulated cellular defenses occur in tissues or across mucosal surfaces, requiring migration of neutrophils from the peripheral blood to areas of infection and inflammation, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Interaction with the endothelium",
"      </strong>",
"      : The first step in this process is the interaction between the neutrophil and vascular endothelial cells. Both leukocytes and endothelial cells express a variety of surface adhesion molecules which help mediate trafficking to an inflamed or infected site. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neutrophil and endothelial cell interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Neutrophil movement to areas of infection or inflammation",
"      </strong>",
"      : In response to the binding of chemoattractants, neutrophils change their shape and crawl by alternating the extrusion and retraction of a frontal lamellipodia, which determines the direction of locomotion. The accuracy of orientation is exquisitely regulated, since the cell can detect a 2 percent change in chemoattractant concentration. Neutrophils move at speeds up to 30 micrometers per minute, thereby qualifying as the fastest cell in the body. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neutrophil movement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/1\">",
"      Liu L, Kubes P. Molecular mechanisms of leukocyte recruitment: organ-specific mechanisms of action. Thromb Haemost 2003; 89:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/2\">",
"      Middleton J, Patterson AM, Gardner L, et al. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002; 100:3853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/3\">",
"      Liu Y, Shaw SK, Ma S, et al. Regulation of leukocyte transmigration: cell surface interactions and signaling events. J Immunol 2004; 172:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/4\">",
"      Wong CH, Heit B, Kubes P. Molecular regulators of leucocyte chemotaxis during inflammation. Cardiovasc Res 2010; 86:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/5\">",
"      Woodfin A, Voisin MB, Nourshargh S. Recent developments and complexities in neutrophil transmigration. Curr Opin Hematol 2010; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/6\">",
"      McDonald B, Kubes P. Cellular and molecular choreography of neutrophil recruitment to sites of sterile inflammation. J Mol Med (Berl) 2011; 89:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/7\">",
"      Chavakis T, Preissner KT, Santoso S. Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thromb Haemost 2003; 89:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/8\">",
"      Yadav R, Larbi KY, Young RE, Nourshargh S. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 2003; 90:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/9\">",
"      Smith CW, Kishimoto TK, Abbassi O, et al. Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitro. J Clin Invest 1991; 87:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/10\">",
"      Luscinskas FW, Brock AF, Arnaout MA, Gimbrone MA Jr. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol 1989; 142:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/11\">",
"      Furie MB, Burns MJ, Tancinco MC, et al. E-selectin (endothelial-leukocyte adhesion molecule-1) is not required for the migration of neutrophils across IL-1-stimulated endothelium in vitro. J Immunol 1992; 148:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/12\">",
"      Borregaard N, Lollike K, Kjeldsen L, et al. Human neutrophil granules and secretory vesicles. Eur J Haematol 1993; 51:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/13\">",
"      Monboisse JC, Garnotel R, Bellon G, et al. The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem 1994; 269:25475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/14\">",
"      Werr J, Johansson J, Eriksson EE, et al. Integrin alpha(2)beta(1) (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue. Blood 2000; 95:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/15\">",
"      Parkos CA, Colgan SP, Liang TW, et al. CD47 mediates post-adhesive events required for neutrophil migration across polarized intestinal epithelia. J Cell Biol 1996; 132:437.",
"     </a>",
"    </li>",
"    <li>",
"     Stossel TP. The mechanical responses of white blood cells. In: Inflammation: Basic Principles and Clinical Correlates, 2nd, Gallin JI, Goldstein IM, Snyderman R (Eds), Raven Press, New York 1992. p.459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/17\">",
"      Hartman RS, Lau K, Chou W, Coates TD. The fundamental motor of the human neutrophil is not random: evidence for local non-Markov movement in neutrophils. Biophys J 1994; 67:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/18\">",
"      Coates TD, Watts RG, Hartman R, Howard TH. Relationship of F-actin distribution to development of polar shape in human polymorphonuclear neutrophils. J Cell Biol 1992; 117:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/19\">",
"      Devreotes PN, Zigmond SH. Chemotaxis in eukaryotic cells: a focus on leukocytes and Dictyostelium. Annu Rev Cell Biol 1988; 4:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/20\">",
"      Zigmond SH, Levitsky HI, Kreel BJ. Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis. J Cell Biol 1981; 89:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/21\">",
"      Stossel TP. The E. Donnall Thomas Lecture, 1993. The machinery of blood cell movements. Blood 1994; 84:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/22\">",
"      Ehrengruber MU, Deranleau DA, Coates TD. Shape oscillations of human neutrophil leukocytes: characterization and relationship to cell motility. J Exp Biol 1996; 199:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/23\">",
"      Vicente-Manzanares M, S&aacute;nchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol 2004; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/24\">",
"      Zhelev DV, Hochmuth RM. Mechanically stimulated cytoskeleton rearrangement and cortical contraction in human neutrophils. Biophys J 1995; 68:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/25\">",
"      Ibarrondo FJ, Torres M, Coates TD. Periodic formation of nascent lamellae is driven by changes in the stable F-actin pool of polymorphonuclear neutrophils after stimulation with chemotactic peptide and cross-linking of CD18 or CD61. Cell Motil Cytoskeleton 1999; 44:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/26\">",
"      Wang Y, Chen CL, Iijima M. Signaling mechanisms for chemotaxis. Dev Growth Differ 2011; 53:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/27\">",
"      Maun NA, Speicher DW, DiNubile MJ, Southwick FS. Purification and properties of a Ca(2+)-independent barbed-end actin filament capping protein, CapZ, from human polymorphonuclear leukocytes. Biochemistry 1996; 35:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/28\">",
"      Li Y, Guerrero A, Howard TH. The actin-binding protein, lymphocyte-specific protein 1, is expressed in human leukocytes and human myeloid and lymphoid cell lines. J Immunol 1995; 155:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/29\">",
"      Coates TD, Torkildson JC, Torres M, et al. An inherited defect of neutrophil motility and microfilamentous cytoskeleton associated with abnormalities in 47-Kd and 89-Kd proteins. Blood 1991; 78:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/30\">",
"      Lassing I, Lindberg U. Specificity of the interaction between phosphatidylinositol 4,5-bisphosphate and the profilin:actin complex. J Cell Biochem 1988; 37:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/31\">",
"      Janmey PA. Phosphoinositides and calcium as regulators of cellular actin assembly and disassembly. Annu Rev Physiol 1994; 56:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/32\">",
"      Parent CA, Blacklock BJ, Froehlich WM, et al. G protein signaling events are activated at the leading edge of chemotactic cells. Cell 1998; 95:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/33\">",
"      Rosales C, Jones SL, McCourt D, Brown EJ. Bromophenacyl bromide binding to the actin-bundling protein l-plastin inhibits inositol trisphosphate-independent increase in Ca2+ in human neutrophils. Proc Natl Acad Sci U S A 1994; 91:3534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/34\">",
"      Klotz KN, Jesaitis AJ. Neutrophil chemoattractant receptors and the membrane skeleton. Bioessays 1994; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/35\">",
"      Bokoch GM, Vlahos CJ, Wang Y, et al. Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Biochem J 1996; 315 ( Pt 3):775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/36\">",
"      Nairn AC, Aderem A. Calmodulin and protein kinase C cross-talk: the MARCKS protein is an actin filament and plasma membrane cross-linking protein regulated by protein kinase C phosphorylation and by calmodulin. Ciba Found Symp 1992; 164:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/37\">",
"      Walz A, Burgener R, Car B, et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/38\">",
"      Mayo KH, Yang Y, Daly TJ, et al. Secondary structure of neutrophil-activating peptide-2 determined by 1H-nuclear magnetic resonance spectroscopy. Biochem J 1994; 304 ( Pt 2):371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/39\">",
"      Baggiolini M, Walz A. [Naf/nap-1, a new peptide which activates neutrophil leukocytes]. Schweiz Med Wochenschr 1989; 119:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/40\">",
"      Brandt E, Petersen F, Flad HD. A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity. Mol Immunol 1993; 30:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/41\">",
"      Malkowski MG, Wu JY, Lazar JB, et al. The crystal structure of recombinant human neutrophil-activating peptide-2 (M6L) at 1.9-A resolution. J Biol Chem 1995; 270:7077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/42\">",
"      Konishi K, Takata Y, Yamamoto M, et al. Structure of the gene encoding rat neutrophil chemo-attractant Gro. Gene 1993; 126:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/43\">",
"      Williams LT, Snyderman R, Pike MC, Lefkowitz RJ. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A 1977; 74:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/44\">",
"      Gallin JI, Wright DG, Malech HL, et al. Disorders of phagocyte chemotaxis. Ann Intern Med 1980; 92:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/45\">",
"      Koo C, Lefkowitz RJ, Snyderman R. The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exists in two affinity states. Biochem Biophys Res Commun 1982; 106:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/46\">",
"      Boulay F, Mery L, Tardif M, et al. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 1991; 30:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/47\">",
"      Boulay F, Tardif M, Brouchon L, Vignais P. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem Biophys Res Commun 1990; 168:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/48\">",
"      Normark S, Normark BH, Hornef M. How neutrophils recognize bacteria and move toward infection. Nat Med 2001; 7:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/49\">",
"      Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A 1978; 75:3943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/50\">",
"      Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/51\">",
"      Murphy PM, Gallin EK, Tiffany HL. Characterization of human phagocytic cell receptors for C5A and platelet activating factor expressed in Xenopus oocytes. J Immunol 1990; 145:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/52\">",
"      Baggiolini M, Imboden P, Detmers P. Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). Cytokines 1992; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/53\">",
"      LaRosa GJ, Thomas KM, Kaufmann ME, et al. Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. J Biol Chem 1992; 267:25402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/54\">",
"      Samanta AK, Oppenheim JJ, Matsushima K. Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils. J Exp Med 1989; 169:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/55\">",
"      Schumacher C, Clark-Lewis I, Baggiolini M, Moser B. High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils. Proc Natl Acad Sci U S A 1992; 89:10542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/56\">",
"      Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/57\">",
"      Baggiolini M, Boulay F, Badwey JA, Curnutte JT. Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst. FASEB J 1993; 7:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/58\">",
"      Williams G, Borkakoti N, Bottomley GA, et al. Mutagenesis studies of interleukin-8. Identification of a second epitope involved in receptor binding. J Biol Chem 1996; 271:9579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/59\">",
"      Wells TN, Power CA, Lusti-Narasimhan M, et al. Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996; 59:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/60\">",
"      Carney DF, Hugli TE. Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor. Protein Sci 1993; 2:1391.",
"     </a>",
"    </li>",
"    <li>",
"     Baggiolini M, Dewald B, Walz A. Interleukin-8 and related chemotactic cytokines. In: Inflammation: Basic Principles and Clinical Correlates, 2nd ed, Gallin JI, Goldstein IM, Snyderman R (Eds), Raven Press, New York 1992. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/62\">",
"      Whatley RE, Zimmerman GA, McIntyre TM, Prescott SM. Lipid metabolism and signal transduction in endothelial cells. Prog Lipid Res 1990; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/63\">",
"      Kunz D, Gerard NP, Gerard C. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J Biol Chem 1992; 267:9101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/64\">",
"      Nakamura M, Honda Z, Matsumoto T, et al. Isolation and properties of platelet-activating factor receptor cDNAs. J Lipid Mediat 1993; 6:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/65\">",
"      Nakamura M, Honda Z, Izumi T, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991; 266:20400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/66\">",
"      Ye RD, Prossnitz ER, Zou AH, Cochrane CG. Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem Biophys Res Commun 1991; 180:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/67\">",
"      O'Flaherty JT, Surles JR, Redman J, et al. Binding and metabolism of platelet-activating factor by human neutrophils. J Clin Invest 1986; 78:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/68\">",
"      Smiley PL, Stremler KE, Prescott SM, et al. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991; 266:11104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/69\">",
"      Bozza PT, Payne JL, Goulet JL, Weller PF. Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. J Exp Med 1996; 183:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/70\">",
"      O'Flaherty JT, Kuroki M, Nixon AB, et al. 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J Biol Chem 1996; 271:17821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17048/abstract/71\">",
"      O'Flaherty JT, Cordes JF, Lee SL, et al. Chemical and biological characterization of oxo-eicosatetraenoic acids. Biochim Biophys Acta 1994; 1201:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8368 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17048=[""].join("\n");
var outline_f16_41_17048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27128793\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUTROPHIL AND ENDOTHELIAL CELL INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Margination and tethering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rolling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Attachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2720278\">",
"      Intraluminal crawling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transmigration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extravascular migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transepithelial migration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEUTROPHIL MOVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Molecular machinery of movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chemotaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chemoattractants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotactic receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - FMLP receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - C5a receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Chemokine receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Lipid chemoattractant receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27128793\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8368|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/63/19445\" title=\"figure 1\">",
"      Neutrophil migration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/15/13564\" title=\"table 1\">",
"      Expression adhesion molecules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17049="Biology and normal function of von Willebrand factor";
var content_f16_41_17049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology and normal function of von Willebrand factor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Margaret E Rick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17049/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/41/17049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand factor (VWF) is a large multimeric glycoprotein that performs two critical functions in hemostasis: it acts as a bridging molecule at sites of vascular injury for normal platelet adhesion, and under high shear conditions, it promotes platelet aggregation. VWF also acts as a carrier for factor VIII in the circulation, maintaining the normal level of factor VIII by increasing the half-life of factor VIII fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A bleeding disorder, called von Willebrand disease (VWD), occurs when VWF is deficient or qualitatively abnormal. VWD is the most common of the inherited bleeding disorders, with an estimated prevalence in the general population of 1 percent by laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptomatic VWD is less common, approximately 0.01 percent, as estimated in hemostasis clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/4\">",
"     4",
"    </a>",
"    ]. Although it is primarily a congenital disorder, there are also acquired forms of the disease.",
"   </p>",
"   <p>",
"    Evaluation of patients with these disorders has improved our understanding of the functions of VWF and the pathophysiology of VWD. This has taken on greater importance as the role of VWF in thrombotic diseases, such as thrombotic thrombocytopenic purpura and other forms of VWF-mediated thrombosis, is being increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/5-9\">",
"     5-9",
"    </a>",
"    ] and the use of new therapies for inhibiting VWF interactions is being explored [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biology and normal functions of VWF will be reviewed here. The classification, pathophysiology, diagnosis, and treatment of VWD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link\">",
"     \"Treatment of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY OF VWF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for VWF is located on the short arm of chromosome 12 and is composed of 178 kilobases (kb) and 52 exons [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]; the VWF mRNA contains approximately 9 kb. A pseudogene is present on chromosome 22 that includes exons 23-34 of the VWF gene; these exons correspond to regions of the authentic gene that encode domains A1, A2, and A3 (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Domain structure'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand factor is synthesized in endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/16\">",
"     16",
"    </a>",
"    ] and megakaryocytes as a primary translation product of 2813 amino acids; it subsequently undergoes considerable processing, including dimerization and multimerization to very large forms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/17\">",
"     17",
"    </a>",
"    ]. The primary translation product contains a signal peptide of 22 amino acids followed by a propeptide of 741 residues, also known as von Willebrand antigen II [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and a mature subunit of 2050 amino acids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dimer production occurs early during processing of the protein by formation of disulfide bonds between the C-terminal ends of the pro-VWF within the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/21\">",
"     21",
"    </a>",
"    ]. The addition of N-linked carbohydrate residues also occurs in the endoplasmic reticulum, a process that is critical to the formation of dimers and subsequent exit from this compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/17\">",
"     17",
"    </a>",
"    ]. The pro-VWF dimers are transported to the Golgi, where further glycosylation and sulfation occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/22\">",
"     22",
"    </a>",
"    ] and multimers are formed by disulfide bond formation between the N-termini of the pro-dimers. Cleavage of the prosequence occurs at approximately the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multimers of a spectrum of sizes are formed, some of which are exceedingly large, more than 20 million Da. The presence of the propeptide is necessary for multimer formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/24\">",
"     24",
"    </a>",
"    ], as is a low pH environment and probably calcium ions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Synthesis of VWF is regulated in part by hormones. As an example, VWF production in endothelial cells is increased by both estrogen and thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and increased estrogen levels during pregnancy lead to higher levels of VWF during the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Storage and secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The smaller multimers of VWF, which represent the majority of the newly synthesized protein, are constitutively secreted from endothelial cells and megakaryocytes, while the remaining VWF, which includes the larger multimers, is targeted to cytoplasmic storage granules [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The storage granules in the endothelial cells (Weibel-Palade bodies) contain these larger VWF multimers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/30\">",
"     30",
"    </a>",
"    ], in addition to the cleaved VWF propeptide, a cell adhesion molecule (P-selectin), a lysosomal membrane sialoglycoprotein (CD63), and angiopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the packaging of VWF in the Weible-Palade bodies and the release of VWF into the circulation are not fully understood, these processes may yield further targets for treatment modalities for thrombotic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/37\">",
"     37",
"    </a>",
"    ]. The alpha granules of platelets serve as the storage site for VWF and P-selectin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/38\">",
"     38",
"    </a>",
"    ]. P-selectin anchors VWF as it is secreted from the Weible-Palade bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/39\">",
"     39",
"    </a>",
"    ], and anchoring the newly synthesized multimers is thought to play a role in promoting the cleavage of ultralarge prothrombotic VWF multimers by ADAMTS13, removing them from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active secretion of the larger, most functional forms of VWF from the storage sites occurs in response to a number of physiologic agonists, including alpha-adrenergic agonists (such as epinephrine), thrombin, fibrin, and histamine, and after the administration of the vasopressin analogue dDAVP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. DDAVP is used therapeutically to raise VWF levels in disorders such as VWD and uremic platelet dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]; the mechanism by which it releases VWF is not fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Plasma VWF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal concentration of VWF in plasma is 500 to 1000",
"    <span class=\"nowrap\">",
"     microg/dL.",
"    </span>",
"    Platelets contain approximately 15 percent of the quantity of VWF present in an equal quantity of platelet-poor plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/43\">",
"     43",
"    </a>",
"    ]. Plasma VWF concentrations vary widely among normal individuals. The factors responsible for this variability are unclear, but polymorphisms in the VWF gene appear to be important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, post-translational changes affecting the carbohydrate structure of VWF may modify the clearance of the protein, causing some of the variation in VWF levels. In addition to the influence of the carbohydrate structure related to ABO blood type in VWF, a locus called \"modifier of VWF\" has been identified in one strain of mice that alters the carbohydrate structure of VWF and causes rapid clearance, accounting for a decrease in VWF levels in this strain. The abnormal glycosylation is due to a lineage specific alteration in the expression of a glycosyl transferase [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The plasma concentration of VWF is affected by the blood group of the individual. Normal adult subjects with type O blood have approximately 25 to 30 percent lower levels of VWF than those with types A, B, or AB [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/49\">",
"     49",
"    </a>",
"    ]. The reason for this is not fully understood, but a portion of the carbohydrate present on VWF is identical to the blood groups, and influences the survival of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/50-57\">",
"     50-57",
"    </a>",
"    ]. These physiologic differences may not be present during the first year of life, perhaps related to the slow postnatal development of the blood group system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     VWF multimers and ADAMTS13",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VWF multimers released by agents such as DDAVP, thrombin, and collagen include larger multimers than those usually present in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/59\">",
"     59",
"    </a>",
"    ]; processing of the ultralarge VWF multimers (ULVWF) takes place in the plasma within about four hours, and is mediated by the metalloproteinase, ADAMTS13, which is synthesized in, and released from, hepatic stellate cells, megakaryocytes, platelets, and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. This enzyme converts the larger multimers into the slightly smaller forms normally seen in the circulation by cleaving VWF in its A2 domain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/64-70\">",
"     64-70",
"    </a>",
"    ], likely acting preferentially on VWF-platelet complexes under fluid shear stress, which reveals the scissile bond [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In vitro studies performed under static conditions have shown that ADAMTS13 is constitutively released from the Golgi of endothelial cells; it attaches along the entire length of the VWF molecule where it cleaves the newly formed VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/73\">",
"     73",
"    </a>",
"    ]. Factor VIII may play a role in accelerating the proteolysis of these ULVWF multimers by ADAMTS13 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cDNA sequence of ADAMTS13 has been determined; the protein is a member of the ADAMTS family of metalloproteinases (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic importance of the cleaving protease is illustrated by the association of thrombotic thrombocytopenic purpura with antibodies against, or congenital deficiency of, this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In addition, animal studies have revealed that there are spontaneous thrombi formed in microvenules in ADAMTS13",
"    <span class=\"nowrap\">",
"     -/-",
"    </span>",
"    mice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/78\">",
"     78",
"    </a>",
"    ], while in vitro evidence indicates that some inflammatory cytokines (eg, interleukin-8) may stimulate the release of ULVWF and others may inhibit ULVWF cleavage (eg, interleukin-6), suggesting a potential linkage between inflammation and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another mechanism may play a role in the processing of the unusually large multimers; thrombospondin-1, by acting as a protein disulfide reductase, has been shown to reversibly generate new thiol groups in VWF and reduce the size of the multimers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/80\">",
"     80",
"    </a>",
"    ]. The relationship and relative importance of the VWF protease and thrombospondin-1 in the determination of the size of plasma VWF multimers in humans is not known at the present time. However, there is evidence in mice that thrombospondin may inhibit the activity of ADAMTS13, perhaps by competing with the protease for access to VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After processing, plasma VWF consists of a series of multimers varying in size from tetramers to multimers of over 40 subunits (greater than 20 million daltons); the basic repeating unit is either a dimer or a tetramer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. VWF circulates as flexible 2 nm thick strands in a tangled coil configuration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/84\">",
"     84",
"    </a>",
"    ]. Its structure becomes more linear under conditions of high shear stress such as those observed in small vessels or vessels narrowed by atherosclerotic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/85\">",
"     85",
"    </a>",
"    ]. The linear conformation appears to be the functional form for binding to the platelet receptor, glycoprotein Ib (GP Ib), which mediates platelet adhesion and aggregation under conditions of high shear (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/86\">",
"     86",
"    </a>",
"    ]. The normal half-life of circulating VWF is approximately 8 to 12 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Domain structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VWF propeptide is composed of homologous domains, each repeated two to four times; these include three A domains, three B domains, two C domains, and four D domains [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/87\">",
"     87",
"    </a>",
"    ]. Each domain has different functional properties (",
"    <a class=\"graphic graphic_figure graphicRef60152 \" href=\"UTD.htm?33/37/34398\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A1 contains binding sites for platelet GP Ib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , collagen, and ristocetin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A2 contains the cleavage site for ADAMTS13 [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/64,89\">",
"       64,89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A3 contains the primary binding site for collagen [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      C1 contains a binding site for platelet integrin alphaIIb-beta3 (GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/91\">",
"       91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      D' and the contiguous part of D3 contains the binding site for factor VIII [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/92-94\">",
"       92-94",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each mature VWF monomer contains every binding site. The larger multimers provide repeated binding sites and are well suited to act as bridging molecules between the platelet and the injured vessel subendothelium, because the repeated binding sites allow multiple interactions with both platelet receptors and subendothelial structures at sites of injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF VWF",
"    </span>",
"    &nbsp;&mdash;&nbsp;VWF functions in primary hemostasis by forming an adhesive bridge between platelets and vascular subendothelial structures as well as between adjacent platelets at sites of endothelial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/95\">",
"     95",
"    </a>",
"    ]. It also plays a role in fibrin clot formation by acting as a carrier protein for factor VIII which has a greatly shortened half-life unless it is bound to VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/1,96,97\">",
"     1,96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the high molecular weight VWF multimers are the most active form of VWF. The large multimers provide multiple binding sites that can interact with both platelet receptors and subendothelial structures at sites of injury. The ultralarge VWF multimers released from platelets and endothelial cells are even more hemostatically effective than the largest forms of VWF in normal plasma, and they are considered prothrombotic, binding spontaneously to platelets in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The large VWF multimers are stored in secretory granules in endothelial cells (Weibel-Palade bodies) and platelets (alpha granules) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/30,38,99\">",
"     30,38,99",
"    </a>",
"    ]. They are actively secreted by agonists such as thrombin and fibrin, resulting in both luminal and abluminal secretion of VWF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abluminal secretion contributes to the binding of platelets to the subendothelium of injured blood vessels",
"     </li>",
"     <li>",
"      Luminal secretion may increase the local concentration of factor VIII to enhance clot formation at the site of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both plasma and platelet VWF play a role in normal hemostasis, studies in chimeric pigs in which plasma and platelet VWF are dissociated suggest that plasma but not platelet VWF is essential for the development of arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/100\">",
"     100",
"    </a>",
"    ]. Thrombosis occurred as expected in pigs with normal plasma VWF and no platelet VWF, while no thrombosis occurred in pigs with absent plasma VWF but normal platelet VWF. In further studies, ear bleeding times were partially corrected by addition of plasma VWF, but showed less correction in VWD animals expressing only platelet VWF, suggesting that plasma VWF definitely contributes to the maintenance of a normal bleeding time and hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Binding to platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The binding of VWF to platelets and subendothelial components is critical for normal platelet adhesion and for the platelet aggregation that occurs at high shear rates. Binding to platelets requires initial activation or alteration in the structure of VWF so that the binding sites in the A1 domain (",
"    <a class=\"graphic graphic_figure graphicRef60152 \" href=\"UTD.htm?33/37/34398\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/88-90,101\">",
"     88-90,101",
"    </a>",
"    ] can engage the platelet receptor GP Ib-IX-V complex on the platelet surface [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/86,102,103\">",
"     86,102,103",
"    </a>",
"    ]. This binding occurs even on nonactivated platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One or both of the following mechanisms may be important in the activation of circulating VWF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Activation\" may occur as VWF binds to subendothelial structures exposed after endothelial damage, possibly immobilizing and exposing multiple VWF A1 domains toward the vessel lumen where platelets are present [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Activation\" may occur when VWF is exposed to the high shear stresses that are present in small arterioles and atherosclerotic arteries (shear rates",
"      <span class=\"nowrap\">",
"       &gt;1000/second).",
"      </span>",
"      In this setting, the conformation of VWF changes from a globular form to a linear form in which the A1 domains are available for binding to the platelet GP Ib receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have shown that beta 2 glycoprotein I acts to inhibit the binding of \"activated\" VWF to GP Ib and decreases platelet adhesion. Beta 2 glycoprotein I itself binds to VWF and inhibits the interaction between VWF and platelet glycoprotein Ib. In some autoimmune settings, antibodies to beta 2 glycoprotein I remove this inhibition of VWF binding and may contribute to thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Other antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second platelet receptor for VWF, integrin alphaIIb-beta3 (GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa),",
"    </span>",
"    does not bind VWF unless the platelets are activated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/102,104\">",
"     102,104",
"    </a>",
"    ]. With platelet activation, alphaIIb-beta3 undergoes conformational change and becomes accessible on the platelet surface. The platelet activation can be brought about by a variety of agents, including activation induced by GP Ib binding to immobilized VWF. The platelet alphaIIb-beta3-VWF interaction appears to contribute to the final, irreversible binding of platelets to the subendothelium after VWF has bound to GP Ib [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/103\">",
"     103",
"    </a>",
"    ]. The alphaIIb-beta3 interaction with VWF may also contribute to platelet aggregation, especially under high shear conditions; under low shear conditions platelet aggregation is mediated primarily by alphaIIb-beta3 binding to fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/91,104,108,109\">",
"     91,104,108,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Binding to subendothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise components in the subendothelial connective tissue to which VWF binds are not defined. VWF binds to multiple types of collagen (types I, II, III, IV, V, and VI) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], but type VI collagen appears to be especially important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Binding to collagen appears to induce a conformational change within the factor VIII-binding motif of VWF that lowers the affinity for factor VIII, perhaps releasing factor VIII locally to aid in the formation of the fibrin clot [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carrier function for factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII is an important protein cofactor in the pathway of thrombin generation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) The plasma concentration of factor VIII is reduced in patients with hemophilia A and VWD. The low factor VIII concentration in VWD is due, at least in part, to the decreased levels of VWF, since VWF normally protects factor VIII from proteolytic inactivation by activated protein C and its cofactor protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/93,96,97\">",
"     93,96,97",
"    </a>",
"    ]. Without VWF, the half-life of factor VIII in the circulation is only about two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/1\">",
"     1",
"    </a>",
"    ].The inactivation of factor VIII by activated protein C is slowed 10- to 20-fold in the presence of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The effect of the low factor VIII concentration is that patients with VWD have a defect in fibrin clot formation as well as a reduction in primary platelet plug formation.",
"   </p>",
"   <p>",
"    VWF can bind factor VIII only when factor VIII has not been cleaved by thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/115\">",
"     115",
"    </a>",
"    ]. After thrombin cleavage, activated factor VIII (fVIIIa) is released from VWF and becomes a fully functional, active cofactor in ongoing thrombin generation, and it then can be inactivated by activated protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17049/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H778077959\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H778078165\">",
"    <span class=\"h2\">",
"     VWF function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand factor (VWF) is a large multimeric glycoprotein that performs a number of critical functions in hemostasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VWF acts as a bridging molecule for normal platelet adhesion at sites of vascular injury, and under high shear conditions, it promotes normal platelet aggregation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Binding to platelets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Binding to subendothelium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VWF acts as a carrier for factor VIII in the circulation, increasing the factor VIII half-life fivefold and maintaining normal levels of factor VIII in the circulation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Carrier function for factor VIII'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bleeding disorder, von Willebrand disease (VWD), occurs when VWF is deficient or qualitatively abnormal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"       \"Classification and pathophysiology of von Willebrand disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H778078017\">",
"    <span class=\"h2\">",
"     VWF biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;VWF is synthesized in endothelial cells and megakaryocytes, regulated in part by estrogen and thyroid hormones. Multimers of a spectrum of sizes are formed, some of which are more than 20 million Da. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Biology of VWF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The smaller multimers of VWF, which represent the majority of the newly synthesized protein, are constitutively secreted from endothelial cells and megakaryocytes, while the remaining VWF, which includes the larger, more functional multimers, is targeted to cytoplasmic storage granules.",
"     </li>",
"     <li>",
"      Active secretion of the larger, most functional forms of VWF (including ultralarge forms of VWF) from the storage sites occurs in response to a number of physiologic agonists, including alpha-adrenergic agonists (eg, epinephrine), thrombin, fibrin, and histamine, and after the administration of the vasopressin analogue DDAVP.",
"     </li>",
"     <li>",
"      The plasma concentration of VWF is affected by the blood group of the individual. Normal subjects with type O blood have approximately 30 percent lower levels of VWF than those with types A, B, or AB. VWF levels are elevated during the second and third trimesters of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H624057#H624057\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Variations in VWF levels in health and disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Processing of &ldquo;prothrombotic&rdquo; ultralarge VWF multimers (ULVWF) takes place in the plasma and is mediated by the metalloproteinase, ADAMTS13. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'VWF multimers and ADAMTS13'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic importance of ADAMTS13 is illustrated by the association of thrombotic thrombocytopenic purpura with antibodies against, or congenital deficiency of, this enzyme. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H778078191\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment of VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification, diagnosis, and treatment of VWD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link\">",
"     \"Treatment of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/1\">",
"      Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/2\">",
"      De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113:5049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/3\">",
"      Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/4\">",
"      Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/5\">",
"      Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/6\">",
"      Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/7\">",
"      Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/8\">",
"      Diener JL, Daniel Lagass&eacute; HA, Duerschmied D, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009; 7:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/9\">",
"      Smith NL, Rice KM, Bovill EG, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117:6007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/10\">",
"      De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/11\">",
"      Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/12\">",
"      Lynch DC, Zimmerman TS, Collins CJ, et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985; 41:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/13\">",
"      Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 1985; 82:6394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/14\">",
"      Verweij CL, de Vries CJ, Distel B, et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res 1985; 13:4699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/15\">",
"      Patracchini P, Calzolari E, Aiello V, et al. Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X,t(X;22)(pter;q11.21) translocation. Hum Genet 1989; 83:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/16\">",
"      Hollestelle MJ, Thinnes T, Crain K, et al. Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost 2001; 86:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/17\">",
"      Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/18\">",
"      Montgomery RR, Zimmerman TS. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest 1978; 61:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/19\">",
"      Fay PJ, Kawai Y, Wagner DD, et al. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/20\">",
"      Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/21\">",
"      Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, et al. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/22\">",
"      Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. Blood 1990; 76:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/23\">",
"      Lynch DC, Williams R, Zimmerman TS, et al. Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1983; 80:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/24\">",
"      Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J 1987; 6:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/25\">",
"      Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986; 102:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/26\">",
"      Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem 1989; 264:13497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/27\">",
"      Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/28\">",
"      Baumgartner-Parzer SM, Wagner L, Reining G, et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/29\">",
"      Mahieu B, Jacobs N, Mahieu S, et al. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul Fibrinolysis 2007; 18:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/30\">",
"      Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/31\">",
"      Haberichter SL, Fahs SA, Montgomery RR. von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood 2000; 96:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/32\">",
"      Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008; 112:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/33\">",
"      McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/34\">",
"      Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/35\">",
"      Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood 1993; 82:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/36\">",
"      Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/37\">",
"      Valentijn KM, Sadler JE, Valentijn JA, et al. Functional architecture of Weibel-Palade bodies. Blood 2011; 117:5033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/38\">",
"      Cramer EM, Meyer D, le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 1985; 66:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/39\">",
"      Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/40\">",
"      Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1976; 57:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/41\">",
"      Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/42\">",
"      Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/43\">",
"      Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 1975; 141:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/44\">",
"      Keightley AM, Lam YM, Brady JN, et al. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999; 93:4277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/45\">",
"      Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost 2001; 86:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/46\">",
"      Campos M, Sun W, Yu F, et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117:5224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/47\">",
"      Mohlke KL, Nichols WC, Westrick RJ, et al. A novel modifier gene for plasma von Willebrand factor level maps to distal mouse chromosome 11. Proc Natl Acad Sci U S A 1996; 93:15352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/48\">",
"      Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999; 96:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/49\">",
"      Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/50\">",
"      Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 2002; 87:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/51\">",
"      O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/52\">",
"      Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/53\">",
"      O'Donnell JS, McKinnon TA, Crawley JT, et al. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/54\">",
"      Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/55\">",
"      Davies JA, Collins PW, Hathaway LS, Bowen DJ. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group. Blood 2007; 109:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/56\">",
"      Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/57\">",
"      Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/58\">",
"      Klarmann D, Eggert C, Geisen C, et al. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion 2010; 50:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/59\">",
"      Fernandez MF, Ginsberg MH, Ruggeri ZM, et al. Multimeric structure of platelet factor VIII/von Willebrand factor: the presence of larger multimers and their reassociation with thrombin-stimulated platelets. Blood 1982; 60:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/60\">",
"      Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/61\">",
"      Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/62\">",
"      Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/63\">",
"      Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/64\">",
"      Furlan M, Robles R, L&auml;mmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/65\">",
"      Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87:4235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/66\">",
"      Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/67\">",
"      Reiter RA, Kn&ouml;bl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/68\">",
"      Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol 2006; 133:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/69\">",
"      Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A 2006; 103:18470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/70\">",
"      Pruss CM, Notley CR, Hegadorn CA, et al. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br J Haematol 2008; 143:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/71\">",
"      Shim K, Anderson PJ, Tuley EA, et al. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/72\">",
"      Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118:3212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/73\">",
"      Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009; 114:5102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/74\">",
"      Cao W, Krishnaswamy S, Camire RM, et al. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 2008; 105:7416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/75\">",
"      Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/76\">",
"      Plaimauer B, Zimmermann K, V&ouml;lkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/77\">",
"      Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276:41059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/78\">",
"      Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/79\">",
"      Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/80\">",
"      Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001; 193:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/81\">",
"      Pimanda JE, Ganderton T, Maekawa A, et al. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 2004; 279:21439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/82\">",
"      Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/83\">",
"      Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/84\">",
"      Fowler WE, Fretto LJ, Hamilton KK, et al. Substructure of human von Willebrand factor. J Clin Invest 1985; 76:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/85\">",
"      Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/86\">",
"      Vicente V, Houghten RA, Ruggeri ZM. Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J Biol Chem 1990; 265:274.",
"     </a>",
"    </li>",
"    <li>",
"     Sadler JE. The molecular biology of human von Willebrand factor. In: Coagulation and Bleeding Disorders: The Role of Factor VIII and Von Willebrand Factor, Zimmerman TS, Ruggeri ZM (Eds), Dekker, New York 1989. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/88\">",
"      Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1991; 266:18172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/89\">",
"      Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood 1998; 91:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/90\">",
"      Miura S, Li CQ, Cao Z, et al. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000; 275:7539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/91\">",
"      Fujimoto T, Ohara S, Hawiger J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest 1982; 69:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/92\">",
"      Cruz MA, Yuan H, Lee JR, et al. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem 1995; 270:10822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/93\">",
"      Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/94\">",
"      Foster PA, Fulcher CA, Marti T, et al. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262:8443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/95\">",
"      Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/96\">",
"      Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/97\">",
"      Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/98\">",
"      Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/99\">",
"      McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor--structure, function and biological importance. Br J Haematol 2010; 148:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/100\">",
"      Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 1995; 92:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/101\">",
"      Bonnefoy A, Yamamoto H, Thys C, et al. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood 2003; 101:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/102\">",
"      Savage B, Sald&iacute;var E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/103\">",
"      Fredrickson BJ, Dong JF, McIntire LV, L&oacute;pez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998; 92:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/104\">",
"      Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267:11300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/105\">",
"      Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/106\">",
"      Hulstein JJ, Lenting PJ, de Laat B, et al. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/107\">",
"      de Laat B, de Groot PG, Derksen RH, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood 2009; 114:3656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/108\">",
"      Timmons S, Kloczewiak M, Hawiger J. ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets. Proc Natl Acad Sci U S A 1984; 81:4935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/109\">",
"      Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254:5357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/110\">",
"      Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981; 21:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/111\">",
"      Morton LF, Griffin B, Pepper DS, Barnes MJ. The interaction between collagens and factor VIII/von Willebrand factor: investigation of the structural requirements for interaction. Thromb Res 1983; 32:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/112\">",
"      Wu XX, Gordon RE, Glanville RW, et al. Morphological relationships of von Willebrand factor, type VI collagen, and fibrillin in human vascular subendothelium. Am J Pathol 1996; 149:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/113\">",
"      Ross JM, McIntire LV, Moake JL, Rand JH. Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions. Blood 1995; 85:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/114\">",
"      Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem 1999; 274:12300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17049/abstract/115\">",
"      Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263:10451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1366 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17049=[""].join("\n");
var outline_f16_41_17049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H778077959\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY OF VWF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Storage and secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Plasma VWF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - VWF multimers and ADAMTS13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Domain structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FUNCTIONS OF VWF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Binding to platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Binding to subendothelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carrier function for factor VIII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H778077959\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H778078165\">",
"      VWF function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H778078017\">",
"      VWF biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H778078191\">",
"      Diagnosis and treatment of VWD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1366|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/37/34398\" title=\"figure 1\">",
"      VWF mRNA and functional domains",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17050="Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents";
var content_f16_41_17050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Fabien Maldonado, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Andrew H Limper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/41/17050/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/41/17050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse drug reactions (ADRs) due to antineoplastic agents are a common form of iatrogenic injury, and the lungs are a frequent target [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. While some antineoplastic agent-induced ADRs are potentially preventable (particularly those that are related to cumulative dosing), many are idiosyncratic and unpredictable.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the incidence and specific patterns of lung toxicity seen with cytotoxic chemotherapy agents. Separate monographs are available for many of the drugs that are most commonly associated with pulmonary toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=see_link\">",
"     \"Chlorambucil-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/46/33513?source=see_link\">",
"     \"Mitomycin-C pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link\">",
"     \"Taxane-induced pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general discussion of the clinical presentation, pathogenesis, diagnosis, differential diagnosis, and management of antineoplastic agent-induced pulmonary toxicity is covered elsewhere, as is lung toxicity associated with molecularly targeted agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BLEOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BORTEZOMIB AND CARFILZOMIB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4187660\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    is a reversible proteasome inhibitor that is used for the treatment of multiple myeloma and mantle cell lymphoma. In clinical trials, approximately 5 percent of patients report severe (grade 3 or worse) dyspnea, although the specific causality of bortezomib and the role of contributing factors such as anemia, respiratory infection, and cardiac dysfunction is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/4\">",
"     4",
"    </a>",
"    ]. Cases of severe interstitial lung disease (some fatal) have been reported, mainly from Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In addition, a few cases of pulmonary hypertension have been reported in the absence of left heart failure or significant pulmonary parenchymal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The specific incidences of lung toxicity and pulmonary hypertension are unknown.",
"   </p>",
"   <p>",
"    An increased incidence of opportunistic infections is reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    for myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], underscoring the importance of a diagnostic workup to exclude pulmonary infection before concluding that drug toxicity is responsible for respiratory symptoms or radiographic opacities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H9#H9\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Bronchoscopy and bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited information on management. A rapid response to glucocorticoid therapy was noted in one case of pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/5\">",
"     5",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data that address retreatment in patients who develop pulmonary toxicity. In general, we would not rechallenge a patient who developed severe (grade 3 or 4) pulmonary toxicity or any grade of pulmonary hypertension unless there are no other therapeutic alternatives. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4187579\">",
"    <span class=\"h2\">",
"     Carfilzomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"     Carfilzomib",
"    </a>",
"    is an irreversible second generation selective proteasome inhibitor that is used to treat relapsed or refractory multiple myeloma (MM). Carfilzomib has been associated with dyspnea, pulmonary hypertension, and cardiac dysfunction. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an open label study, 266 patients with MM received intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      for up to 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/11\">",
"       11",
"      </a>",
"      ]. Dyspnea was noted in 34 percent, although carfilzomib was considered to be responsible in only one-half of cases. Dyspnea was transient and not associated with progressive lung injury; pulmonary hypertension was not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a separate open-label study, in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      was administered weekly for three of every four weeks up to 12 months to 129 patients with MM, treatment-related dyspnea was reported in 29 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/12\">",
"       12",
"      </a>",
"      ]. Pulmonary hypertension was not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      According to the US Food and Drug Administration-approved manufacturer&rsquo;s prescribing information, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      was associated with development of pulmonary hypertension in 2 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/13\">",
"       13",
"      </a>",
"      ]. Pulmonary hypertension was severe (grade 3 or greater) in less than 1 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear from these reports whether anemia or cardiac dysfunction contributed to dyspnea that was not related to pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H7757908#H7757908\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Proteasome inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who develop severe (grade 3 or 4) dyspnea or pulmonary hypertension while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    , treatment should be withheld at least until respiratory symptoms and signs have resolved. There are no data regarding the safety of carfilzomib rechallenge in these patients. The FDA-approved manufacturer&rsquo;s labeling suggests a dose reduction if carfilzomib is reinstituted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/13\">",
"     13",
"    </a>",
"    ]. However, we generally suggest not rechallenging such patients unless there are no other reasonable therapeutic alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BUSULFAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CARMUSTINE (BCNU)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHLORAMBUCIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=see_link\">",
"     \"Chlorambucil-induced pulmonary injury\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CYCLOPHOSPHAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CYTARABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    is used to induce remission in acute myeloblastic leukemia and in preparation for hematopoietic cell transplantation. Lung toxicity described as noncardiogenic pulmonary edema has been reported in leukemic patients receiving cytarabine at intermediate to high doses (1 to 3 g every 12 hours for four to six days); it develops a median of one to two weeks (range one to 21 days) after initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The overall incidence is unclear. In older reports, up to 14 percent of patients were affected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/15\">",
"     15",
"    </a>",
"    ], but more recent clinical trials suggest much lower rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients present with a subacute development of low-grade fever, mild dyspnea, tachypnea, cough, moderate to severe hypoxemia, and crackles on lung auscultation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/14\">",
"     14",
"    </a>",
"    ]. Chest radiographs show confluent alveolar consolidation with or without pleural effusions. Histopathology may reveal the presence of proteinaceous material in the alveoli without cellular atypia, a nonspecific finding.",
"   </p>",
"   <p>",
"    Discontinuation of the drug is warranted. Otherwise, treatment is essentially supportive and consists of supplemental oxygen, diuresis, and ventilatory support, if needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of glucocorticoid therapy is anecdotal and of unproven value; too few patients in the literature have received glucocorticoid therapy to judge its value. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course is most often characterized by eventual resolution, although fatalities are reported. In a review of 72 published cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    -related pulmonary toxicity not derived from autopsy series, there were 20 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DOXORUBICIN AND RELATED COMPOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antitumor antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , amrubicin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    are inhibitors of topoisomerase II and have been associated with pulmonary toxicity when used alone and in combination with other antineoplastic agents. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24692560\">",
"    <span class=\"h2\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    has a broad range of antitumor activity. Although doxorubicin is far more commonly associated with cumulative cardiac toxicity, several cases of interstitial pneumonia and rarely, organizing pneumonia have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/19\">",
"     19",
"    </a>",
"    ]. Whether lung toxicity was directly attributable to doxorubicin in these case reports is unclear, as all patients were concurrently receiving other agents that are also implicated in causing lung injury. Reactivation of prior radiation pneumonitis (radiation-recall pneumonitis) has also been observed with doxorubicin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited information on management of pneumonitis due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Dyspnea may also be caused by an infusion reaction, which is more commonly seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (Doxil) than with free drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H42#H42\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Anthracyclines and related agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24692523\">",
"    <span class=\"h2\">",
"     Amrubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amrubicin is a novel anthracycline that is approved in Japan for the treatment of small cell lung cancer. The major toxicity is myelosuppression, and cardiac toxicity is minimal. Pulmonary toxicity has been reported, including severe interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Among 100 patients treated with amrubicin, pulmonary toxicity developed in seven, four of whom had preexisting fibrotic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/20\">",
"     20",
"    </a>",
"    ]. The typical presentation was the acute onset of dyspnea, cough, and fever. Computed tomography (CT) scans showed ground-glass opacities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consolidation. Three of six patients treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    improved, but three died of progressive respiratory failure. Thus, the role of glucocorticoid therapy in the treatment of amrubicin-induced pneumonitis is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link&amp;anchor=H4086068#H4086068\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\", section on 'Amrubicin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amrubicin should be used with caution, if at all, in patients with underlying interstitial lung disease, due to the higher rate of lung toxicity observed among those with preexisting pulmonary fibrosis compared with those without (33 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports of interstitial pneumonia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], but most patients were receiving other antineoplastic agents that could have been responsible for the pulmonary toxicity. Severe cases appear to respond rapidly to oral glucocorticoid therapy. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FLUDARABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    is a purine analog that is mainly used in the treatment of indolent lymphoproliferative disorders such as chronic lymphocytic leukemia. Case reports describe interstitial pneumonitis during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]; the incidence was approximately 10 percent in the largest series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/26\">",
"     26",
"    </a>",
"    ]. Most cases develop within weeks of starting drug treatment, although delayed presentations are also reported.",
"   </p>",
"   <p>",
"    Radiographic studies typically show mixed alveolar and interstitial opacities. Nodular opacities that may be concerning for malignancy or fungal infection have also been reported. Histology is non-specific, typically showing interstitial inflammation with mild fibrosis.",
"   </p>",
"   <p>",
"    The onset of dyspnea and cough during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    should always suggest the possibility of drug-induced lung disease. However, opportunistic pulmonary infections are actually more common. Fludarabine induces severe immunosuppression, which increases the recipient's risk of potentially life-threatening infections with unusual pathogens. Patients who develop respiratory symptoms or pulmonary infiltrates with or without fever while receiving fludarabine should undergo a diagnostic bronchoscopy and BAL analysis, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H9#H9\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Bronchoscopy and bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After infection is ruled out as a cause of the symptoms, discontinuation of the drug and administration of glucocorticoids usually leads to prompt resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, fatal complications have been reported. Rechallenge is contraindicated because of the high likelihood of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/26\">",
"     26",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GEMCITABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is a pyrimidine analog that is used mainly for the treatment of pancreatic and advanced non-small cell lung cancer. Up to 23 percent of patients treated with gemcitabine develop dyspnea during treatment, but only a small fraction develop severe dyspnea that is accompanied by radiographic findings.",
"   </p>",
"   <p>",
"    Early reports suggested that significant pulmonary toxicity developed in as many as 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/32\">",
"     32",
"    </a>",
"    ]. More recent series suggest that severe lung toxicity may have been largely overestimated and is probably more in the range of 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]. The highest frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -induced lung toxicity (over 20 percent) has been observed in trials combining gemcitabine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    or a taxane (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The risk of gemcitabine-induced interstitial lung disease is also increased among patients with preexisting pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link&amp;anchor=H6#H6\">",
"     \"Taxane-induced pulmonary toxicity\", section on 'Concomitant drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is a potent radiosensitizer, and concurrent use of radiotherapy may also synergistically worsen gemcitabine-induced lung toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Gemcitabine may also cause radiation recall, a process characterized by reactivation of previous subclinical radiation-induced lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A range of pulmonary toxicities has been described, including interstitial pneumonitis, diffuse alveolar damage, capillary leak syndrome with noncardiogenic pulmonary edema, alveolar hemorrhage, pleural effusions, and acute eosinophilic pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/39,49,50\">",
"     39,49,50",
"    </a>",
"    ]. In a review of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -associated lung injury, dyspnea, fever, and cough associated with new radiographic opacities was the most common presentation and occurred a median of 48 days after institution of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/41\">",
"     41",
"    </a>",
"    ]. The typical radiographic findings are bilateral ground-glass opacities, reticular opacities and thickened septal lines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/39,51\">",
"     39,51",
"    </a>",
"    ]. Centrilobular nodules can also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchoconstriction is rare, as are thrombotic microangiopathy and pulmonary veno-occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/49,52-54\">",
"     49,52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that myelosuppression is the most common adverse reaction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , opportunistic bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    viral lung infections need to be considered in the differential diagnosis of gemcitabine-induced lung toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is generally supportive and includes discontinuation of the drug. For severe cases, a short oral course of glucocorticoids frequently leads to a rapid improvement in clinical and radiographic parameters (within days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/34,35,37,38,52,56\">",
"     34,35,37,38,52,56",
"    </a>",
"    ]. However, fatalities are reported. In one review, the mortality rate with severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    lung toxicity was 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent reintroduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is contraindicated as this may result in fatal pulmonary toxicity. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IFOSFAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    is similar in structure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , which is associated with both early-onset and late onset pulmonary toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are scattered case reports of interstitial pneumonia during treatment with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, there are other reports of pneumonitis (at times fatal) occurring in patients treated with ifosfamide in combination with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/7\">",
"     7",
"    </a>",
"    ]; the contribution of ifosfamide to the development of pneumonitis in these cases is unclear.",
"   </p>",
"   <p>",
"    For patients who develop shortness of breath while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , the differential diagnosis should include methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of glucocorticoids in the management of severe interstitial pneumonitis in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    is unclear as there are no published reports. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IRINOTECAN AND TOPOTECAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonitis is a dose-limiting side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , a semi-synthetic camptothecin that is used most commonly for treatment of advanced colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dyspnea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary toxicity of any grade have been reported in 0 to 20 percent of patients treated on clinical trials using standard doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. However, the incidence of severe lung toxicity with irinotecan alone is probably in the range of 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/64\">",
"     64",
"    </a>",
"    ], with the higher rates initially observed in the United States related to the concurrent use of other antineoplastic agents (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/65\">",
"     65",
"    </a>",
"    ]) and radiotherapy in patients with thoracic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary toxicity is characterized by the nonspecific onset of cough, shortness of breath, and fever. Radiographic studies demonstrate reticulonodular infiltrates and occasional pleural effusions.",
"   </p>",
"   <p>",
"    Discontinuation of the treatment is warranted. Glucocorticoids have been used in a couple of case reports with good response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/62,68\">",
"     62,68",
"    </a>",
"    ]. However, deaths have been reported in spite of the institution of empiric glucocorticoid therapy, even after a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/62\">",
"     62",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    , a related agent, has only rarely been associated with pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The reported patterns include organizing pneumonia, diffuse alveolar damage, and in rare cases, constrictive bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MELPHALAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    is an alkylating agent used in the treatment of multiple myeloma. Rarely, acute pneumonitis and acute bronchoconstriction have been attributed to this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Management typically includes discontinuation of the drug and initiation of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/72\">",
"     72",
"    </a>",
"    ]. Inhaled beta-adrenergic agents are used to treat bronchoconstriction. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     METHOTREXATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MITOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/46/33513?source=see_link\">",
"     \"Mitomycin-C pulmonary toxicity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OXALIPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    , which is used in combination with 5-fluorouracil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    mainly for the treatment of advanced colorectal cancer, has rarely been associated with lung toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. The described patterns include interstitial pneumonia, cryptogenic organizing pneumonia, eosinophilic pneumonia, and diffuse alveolar damage.",
"   </p>",
"   <p>",
"    There are case reports of complete resolution with supportive treatment and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/75,78\">",
"     75,78",
"    </a>",
"    ], although fatalities are described even with empiric glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/76,77,80\">",
"     76,77,80",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PODOPHYLLOTOXINS: ETOPOSIDE AND TENIPOSIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    (VP-16) is a topoisomerase II inhibitor widely used for the treatment of bronchogenic carcinoma. Approximately 1 to 3 percent of patients treated with intravenous (IV) etoposide have a hypersensitivity reaction with features of anaphylaxis (angioedema, chest discomfort, bronchoconstriction, and hypotension); the reaction is thought due to the vehicle rather than the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H64#H64\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Etoposide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, pulmonary toxicity appears to be infrequent with most of the cases occurring after prolonged oral rather than IV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. Earlier presentations may sometimes be observed. The reaction is characterized histopathologically by diffuse alveolar damage with atypical type 2 pneumocytes. Treatment relies on discontinuation of the agent. Some cases have been treated with corticosteroids, though data supporting their use is not available.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    can also increase the risk of radiation pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"     Teniposide",
"    </a>",
"    , another podophyllotoxin agent that is used for the treatment of lung cancer and refractory childhood acute lymphoblastic leukemia, has not been associated with pneumonitis. However, drug infusions are associated with hypersensitivity reactions (acute onset of dyspnea and bronchoconstriction typically within the first 10 to 20 minutes) in 4 to 7 percent of cases. The vehicle, Cremophor (ie, polyoxyethylated castor oil, the same vehicle used for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ), is thought to be responsible for these manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H34#H34\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Mechanisms of infusion reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROCARBAZINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    causes a pneumonitis that is thought to be a hypersensitivity phenomenon, as it is characterized by acute onset and associated with eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/85\">",
"     85",
"    </a>",
"    ]. Resolution usually follows discontinuation of the agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TAXANES: PACLITAXEL AND DOCETAXEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=see_link\">",
"     \"Taxane-induced pulmonary toxicity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TEMOZOLOMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , an oral alkylating agent used mainly in the treatment of brain tumors, may have caused pneumonitis in 2 to 5 percent of patients in phase II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. One case of organizing pneumonia has been described that resolved after drug discontinuation and treatment with oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/88\">",
"     88",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THALIDOMIDE AND RELATED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is mainly used for treatment of multiple myeloma. The most common pulmonary side effect is dyspnea, which is reported in up to one-half patients, but severe pulmonary symptoms (grade 3 or 4) occur in fewer than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is also associated with an increased risk of thromboembolic disease, particularly when used in association with other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has also been associated with rare cases of non-thromboembolic pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    induced pneumonitis is extremely rare, but interstitial fibrosis, lymphocytic alveolitis, eosinophilic pneumonia, and organizing pneumonia have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/95-101\">",
"     95-101",
"    </a>",
"    ]. An increased incidence of opportunistic infections is reported in patients receiving thalidomide for myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/102-104\">",
"     102-104",
"    </a>",
"    ], underscoring the importance of a diagnostic workup to exclude pulmonary infection patients who develop respiratory symptoms or pulmonary infiltrates while receiving thalidomide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H9#H9\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Bronchoscopy and bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is an analog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    with fewer nonhematologic side effects. Dyspnea and cough of any grade are reported in about 15 percent of patients, 4 percent severe [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/105\">",
"     105",
"    </a>",
"    ]. In addition, pneumonitis is reported in about 10 percent of cases, about one-half are severe (grade 3 to 4, (",
"    <a class=\"graphic graphic_table graphicRef61493 \" href=\"UTD.htm?18/50/19243\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. General aspects of management of suspected lung toxicity with antineoplastic agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    is also associated with an increased risk of thromboembolic disease, particularly when used in association with other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     VINCA ALKALOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of lung toxicity have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    . Bronchoconstriction, interstitial pneumonitis, lung nodules and non-cardiogenic pulmonary edema have been observed with vinblastine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Vinorelbine has also been associated with interstitial pneumonitis as a single agent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/41/17050/abstract/110-112\">",
"     110-112",
"    </a>",
"    ], but in most of the case reports, the drug was given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , complicating the assessment of causality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8268586\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse drug reactions due to antineoplastic agents are a common form of iatrogenic injury, and the lungs are a frequent target. While some reactions are related to the cumulative dose (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ), many are idiosyncratic and unpredictable.",
"     </li>",
"     <li>",
"      The most common patterns of lung toxicity include interstitial pneumonitis (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , anthracyclines and anthracycline-like agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , vinca alkaloids), organizing pneumonia (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , oxaliplatin), diffuse alveolar damage (gemcitabine, oxaliplatin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ), opportunistic infections (bortezomib, fludarabine), noncardiogenic pulmonary edema (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , gemcitabine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ), radiation recall pneumonitis (doxorubicin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , gemcitabine), eosinophilic pneumonia (gemcitabine, oxaliplatin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ), alveolar hemorrhage (gemcitabine), nonthromboembolic pulmonary hypertension (thalidomide), and thromboembolic disease, which may affect the lungs (thalidomide and lenalidomide).",
"     </li>",
"     <li>",
"      In most cases, the risk of lung toxicity associated with each drug is small (&lt;10 percent), and the respiratory adverse reaction is generally reversible with drug discontinuation. However, fatalities have been reported.",
"     </li>",
"     <li>",
"      A general discussion of the clinical presentation, pathogenesis, diagnosis, differential diagnosis, and management of antineoplastic agent-induced pulmonary toxicity is covered elsewhere, as is lung toxicity associated with molecularly targeted agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=see_link\">",
"       \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/1\">",
"      Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/2\">",
"      Rosenow EC 3rd, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect 1995; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/3\">",
"      Snyder LS, Hertz MI. Cytotoxic drug-induced lung injury. Semin Respir Infect 1988; 3:217.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration prescribing information for bortezomib. file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7#nlm34084-4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/5\">",
"      Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007; 25:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/6\">",
"      Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107:3492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/7\">",
"      Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/8\">",
"      Mateos MV, Hern&aacute;ndez JM, Hern&aacute;ndez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/9\">",
"      Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/10\">",
"      Wondergem MJ, Gr&uuml;nberg K, Wittgen BP, et al. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology 2009; 54:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/11\">",
"      Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/12\">",
"      Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration prescribing information for carfilzomib. file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf (Accessed on August 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/14\">",
"      Forghieri F, Luppi M, Morselli M, Potenza L. Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica 2007; 92:e85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/15\">",
"      Andersson BS, Luna MA, Yee C, et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 1990; 65:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/16\">",
"      Jehn U, G&ouml;ldel N, Rienm&uuml;ller R, Wilmanns W. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia. Med Oncol Tumor Pharmacother 1988; 5:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/17\">",
"      Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005; 105:3420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/18\">",
"      Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/19\">",
"      Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol) 2002; 14:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/20\">",
"      Yoh K, Kenmotsu H, Yamaguchi Y, et al. Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 2010; 5:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/21\">",
"      Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008; 26:5401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/22\">",
"      Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007; 25:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/23\">",
"      Ryu JH. Chemotherapy-induced pulmonary toxicity in lung cancer patients. J Thorac Oncol 2010; 5:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/24\">",
"      Tomlinson J, Tighe M, Johnson S, et al. Interstitial pneumonitis following mitozantrone, chlorambucil and prednisolone (MCP) chemotherapy. Clin Oncol (R Coll Radiol) 1999; 11:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/25\">",
"      Matsukawa Y, Takeuchi J, Aiso M, et al. Interstitial pneumonitis possibly due to mitoxantrone. Acta Haematol 1993; 90:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/26\">",
"      Helman DL Jr, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest 2002; 122:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/27\">",
"      Hurst PG, Habib MP, Garewal H, et al. Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 1987; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/28\">",
"      Cervantes F, Salgado C, Montserrat E, Rozman C. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis. Lancet 1990; 336:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/29\">",
"      Kane GC, McMichael AJ, Patrick H, Erslev AJ. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate. Respir Med 1992; 86:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/30\">",
"      Stoica GS, Greenberg HE, Rossoff LJ. Corticosteroid responsive fludarabine pulmonary toxicity. Am J Clin Oncol 2002; 25:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/31\">",
"      Levin M, Aziz M, Opitz L. Steroid-responsive interstitial pneumonitis after fludarabine therapy. Chest 1997; 111:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/32\">",
"      Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002; 132:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/33\">",
"      Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anticancer Drugs 1998; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/34\">",
"      Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002; 20:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/35\">",
"      Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/36\">",
"      Linskens RK, Golding RP, van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med 2000; 56:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/37\">",
"      Marruchella A, Fiorenzano G, Merizzi A, et al. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/38\">",
"      Barl&eacute;si F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/39\">",
"      Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000; 24:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/40\">",
"      Sauer-Heilborn A, Kath R, Schneider CP, H&ouml;ffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/41\">",
"      Belknap SM, Kuzel TM, Yarnold PR, et al. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 2006; 106:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/42\">",
"      Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/43\">",
"      Umemura S, Yamane H, Suwaki T, et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol 2011; 137:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/44\">",
"      Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 51:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/45\">",
"      van Putten JW, Price A, van der Leest AH, et al. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003; 9:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/46\">",
"      Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/47\">",
"      Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002; 20:4191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/48\">",
"      Jeter MD, J&auml;nne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/49\">",
"      Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/50\">",
"      Kim YH, Mishima M, Yoshizawa A. Gemcitabine-induced acute eosinophilic pneumonia. J Thorac Oncol 2010; 5:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/51\">",
"      Tamura M, Saraya T, Fujiwara M, et al. High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-Induced Cases. Oncologist 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/52\">",
"      Gupta N, Ahmed I, Steinberg H, et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/53\">",
"      Nelson R, Trassoff P. Dyspnea with gemcitabine is commonly seen, often disease related, transient, and rarely severe. Eur J Cancer 1999; 31:S197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/54\">",
"      Rosado MF, Kett DH, Schein RM, et al. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 2002; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/55\">",
"      Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/56\">",
"      Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/57\">",
"      Baker WJ, Fistel SJ, Jones RV, Weiss RB. Interstitial pneumonitis associated with ifosfamide therapy. Cancer 1990; 65:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/58\">",
"      Elliott TE, Buckner JC, Cascino TL, et al. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neurooncol 1991; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/59\">",
"      Hadjiliadis D, Govert JA. Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. Chest 2000; 118:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/60\">",
"      Yamada M, Kudoh S, Fukuda H, et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer 2002; 87:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/61\">",
"      Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/62\">",
"      Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000; 11:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/63\">",
"      Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/64\">",
"      Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/65\">",
"      Rocha-Lima CM, Herndon JE 2nd, Lee ME, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 2007; 18:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/66\">",
"      Yamada K, Ikehara M, Tanaka G, et al. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 2004; 66:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/67\">",
"      Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998; 34:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/68\">",
"      Michielin O, Udry E, P&eacute;riard D, et al. Irinotecan-induced interstitial pneumonia. Lancet Oncol 2004; 5:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/69\">",
"      Maitland ML, Wilcox R, Hogarth DK, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 2006; 54:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/70\">",
"      Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/71\">",
"      Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchiolitis. South Med J 2004; 97:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/72\">",
"      Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/73\">",
"      Goucher G, Rowland V, Hawkins J. Melphalan-induced pulmonary interstitial fibrosis. Chest 1980; 77:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/74\">",
"      Westerfield BT, Michalski JP, McCombs C, Light RW. Reversible melphalan-induced lung damage. Am J Med 1980; 68:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/75\">",
"      Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med 2008; 102:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/76\">",
"      Gagnadoux F, Roiron C, Carrie E, et al. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol 2002; 25:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/77\">",
"      Pasetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol 2006; 12:5907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/78\">",
"      Garrido M, O'Brien A, Gonz&aacute;lez S, et al. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest 2007; 132:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/79\">",
"      Watkins J, Slade JH, Phan A, et al. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer 2011; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/80\">",
"      Ar&eacute;valo Lobera S, Sagastibeltza Mari&ntilde;elarena N, Elejoste Echeberr&iacute;a I, et al. Fatal pneumonitis induced by oxaliplatin. Clin Transl Oncol 2008; 10:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/81\">",
"      Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer 1999; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/82\">",
"      Hatakeyama S, Tachibana A, Morita M, et al. [Etoposide-induced pneumonitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/83\">",
"      Uchida T, Nakakawaji K, Sakamoto J. [Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect]. Gan To Kagaku Ryoho 1996; 23:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/84\">",
"      Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/85\">",
"      Mahmood T, Mudad R. Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol 2002; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/86\">",
"      Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/87\">",
"      Brandwein JM, Yang L, Schimmer AD, et al. A phase II study of temozolomide therapy for poor-risk patients aged &gt;or=60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 2007; 21:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/88\">",
"      Maldonado F, Limper AH, Lim KG, Aubrey MC. Temozolomide-associated organizing pneumonitis. Mayo Clin Proc 2007; 82:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/89\">",
"      Gordinier ME, Dizon DS. Dyspnea during thalidomide treatment for advanced ovarian cancer. Ann Pharmacother 2005; 39:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/90\">",
"      Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/91\">",
"      Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/92\">",
"      Lafaras C, Mandala E, Verrou E, et al. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol 2008; 19:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/93\">",
"      Antonioli E, Nozzoli C, Gianfaldoni G, et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 2005; 16:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/94\">",
"      Younis TH, Alam A, Paplham P, et al. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 2003; 121:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/95\">",
"      Feaver AA, McCune DE, Mysliwiec AG, Mysliwiec V. Thalidomide-induced organizing pneumonia. South Med J 2006; 99:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/96\">",
"      Sasaki M, Isobe Y, Tsukune Y, et al. Thalidomide may induce interstitial pneumonia preferentially in Japanese patients. Eur J Haematol 2009; 82:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/97\">",
"      Onozawa M, Hashino S, Sogabe S, et al. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. J Clin Oncol 2005; 23:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/98\">",
"      Hattori Y, Okamoto S, Shimada N, et al. Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile. Cancer Sci 2008; 99:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/99\">",
"      Buttin BM, Moore MJ. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. Gynecol Oncol 2008; 111:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/100\">",
"      Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/101\">",
"      Tilluckdharry L, Dean R, Farver C, Ahmad M. Thalidomide-Related Eosinophilic Pneumonia: A case report and brief literature review. Cases J 2008; 1:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/102\">",
"      Curley MJ, Hussein SA, Hassoun PM. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 2002; 40:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/103\">",
"      Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/104\">",
"      Sch&uuml;tt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/105\">",
"      Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/106\">",
"      Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/107\">",
"      Amraoui K, Belhadj K, Ma&icirc;tre B, et al. Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients. Eur Respir Rev 2013; 22:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/108\">",
"      Hoelzer KL, Harrison BR, Luedke SW, Luedke DW. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell Clin Pharm 1986; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/109\">",
"      Rao SX, Ramaswamy G, Levin M, McCravey JW. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985; 145:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/110\">",
"      Igishi T, Shigeoka Y, Yasuda K, et al. UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study. J Thorac Oncol 2009; 4:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/111\">",
"      Furuse K, Kubota K, Kawahara M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 1994; 11:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/41/17050/abstract/112\">",
"      Yanagitani N, Shimizu Y, Kaira K, et al. Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer. Gan To Kagaku Ryoho 2008; 35:1619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4327 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17050=[""].join("\n");
var outline_f16_41_17050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8268586\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BLEOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BORTEZOMIB AND CARFILZOMIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4187660\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4187579\">",
"      Carfilzomib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BUSULFAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CARMUSTINE (BCNU)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHLORAMBUCIL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CYCLOPHOSPHAMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CYTARABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DOXORUBICIN AND RELATED COMPOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24692560\">",
"      Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24692523\">",
"      Amrubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FLUDARABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GEMCITABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IFOSFAMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IRINOTECAN AND TOPOTECAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MELPHALAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      METHOTREXATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MITOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OXALIPLATIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PODOPHYLLOTOXINS: ETOPOSIDE AND TENIPOSIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROCARBAZINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TAXANES: PACLITAXEL AND DOCETAXEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TEMOZOLOMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THALIDOMIDE AND RELATED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      VINCA ALKALOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8268586\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19243\" title=\"table 1\">",
"      NCI CTCAE pneumonitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41380?source=related_link\">",
"      Chlorambucil-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/46/33513?source=related_link\">",
"      Mitomycin-C pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38344?source=related_link\">",
"      Taxane-induced pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_41_17051="Abnormal vital signs";
var content_f16_41_17051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thresholds for defining abnormal vital signs in a potential pediatric organ donor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormal vital signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        RR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulse",
"       </td>",
"       <td class=\"subtitle1\">",
"        SBP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonate",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        &gt;160",
"       </td>",
"       <td>",
"        &lt;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        &gt;160",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toddler",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        &gt;140",
"       </td>",
"       <td>",
"        &lt;75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School age",
"       </td>",
"       <td>",
"        &gt;25",
"       </td>",
"       <td>",
"        &gt;120",
"       </td>",
"       <td>",
"        &lt;85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adolescent",
"       </td>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        &gt;110",
"       </td>",
"       <td>",
"        &lt;90",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.2. Copyright &copy;2008 NATCO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17051=[""].join("\n");
var outline_f16_41_17051=null;
var title_f16_41_17052="ACC AHA HRS pacing acute MI";
var content_f16_41_17052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS guideline summary: Permanent pacing after the acute phase of myocardial infarction (MI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that  permanent pacing after the acute phase of MI should be performed in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Persistent second-degree AV block in the His-Purkinje system with alternating bundle branch block or third-degree AV block within or below the His-Purkinje system after ST-segment elevation MI. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Transient advanced second- or third-degree infranodal AV block and associated bundle branch block. If the site of block is uncertain, an eletrophysiological study may be necessary. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Persistent and symptomatic second- or third-degree AV block. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The evidence or opinion is less well established that permanent pacing after the acute phase of MI is beneficial in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Persistent second- or third-degree AV block at the AV node level, even in the absence of symptoms. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence that permanent pacing after the acute phase of MI is not useful and may be harmful in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Transient AV block in the absence of intraventricular conduction defects. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Transient AV block in the presence of isolated left anterior fascicular block. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; New bundle branch block or fascicular block in the absence of AV block. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Persistent asymptomatic first-degree AV block in the presence of bundle branch or fascicular block. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17052=[""].join("\n");
var outline_f16_41_17052=null;
var title_f16_41_17053="Interpretation neonatal hyperoxia test";
var content_f16_41_17053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hyperoxia test results in neonates with cyanosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (percent saturation)",
"        <br/>",
"        when FiO",
"        <sub>",
"         2",
"        </sub>",
"        = 0.21",
"       </td>",
"       <td class=\"subtitle1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (percent saturation)",
"        <br/>",
"        when Fi0",
"        <sub>",
"         2",
"        </sub>",
"        = 1.0",
"       </td>",
"       <td class=\"subtitle1\">",
"        PaCO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;70 (&gt;95)",
"       </td>",
"       <td>",
"        &gt;300 (100)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary disease",
"       </td>",
"       <td colspan=\"2\">",
"        50 (85)",
"       </td>",
"       <td>",
"        &gt;150 (100)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic disease",
"       </td>",
"       <td colspan=\"2\">",
"        50 (85)",
"       </td>",
"       <td>",
"        &gt;150 (100)",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"       <td colspan=\"2\">",
"        &gt;70 (&lt;85)",
"       </td>",
"       <td>",
"        &gt;200 (&lt;85)",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parallel circulation*",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &lt;40 (&lt;75)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;50 (&lt;85)",
"       </td>",
"       <td class=\"sublist_other\">",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixing with reduced PBF",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        &lt;40 (&lt;75)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;50 (&lt;85)",
"       </td>",
"       <td class=\"sublist_other\">",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixing without restricted PBF",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        40 to 60 (75 to 93)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;150 (&lt;100)",
"       </td>",
"       <td class=\"sublist_other\">",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Preductal",
"       </td>",
"       <td class=\"subtitle2\">",
"        Postductal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Differential cyanosis",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        70 (95)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;40 (&lt;75)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Variable",
"       </td>",
"       <td class=\"sublist_other\">",
"        35 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reverse differential cyanosis",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;40 (&lt;75)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;50 (&gt;90)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperoxia test: The typical results of partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) and percent of oxygen saturation following administration of room air (FiO",
"    <sub>",
"     2",
"    </sub>",
"    = 0.21) or 100 percent oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    = 1.0) to neonates with different causes of cyanosis.",
"    <div class=\"footnotes\">",
"     * D-transposition of the great arteries with or without ventricular septal defect.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Tricuspid atresia with pulmonary stenosis or pulmonary atresia, pulmonary atresia or critical pulmonary stenosis with intact ventricular septum, tetralogy of Fallot.",
"      <br>",
"       &Delta; Truncus arteriosus, total anomalous pulmonary venous connection without obstruction, hypoplastic left heart syndrome, single ventricle without pulmonary stenosis of pulmonary atresia.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Persistent pulmonary hypertension of the newborn, interrupted aortic arch, severe coarctation.",
"        <br>",
"         &sect; D-transposition of the great arteries associated with either coarctation or suprasystemic pulmonary vascular resistance.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clin Perinatol 2001; 28:91. Copyright &copy; 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17053=[""].join("\n");
var outline_f16_41_17053=null;
var title_f16_41_17054="Functional class outcome AR";
var content_f16_41_17054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preoperative functional class predicts outcome after valve replacement for aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 480px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients who preoperatively have functional class III or IV symptoms have a lower survival rate compared to those with functional class I or II regardless of whether the left ventricular ejection fraction (LVEF) is &ge;50 percent (upper panel) or &lt;50 percent (lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klodas, E, Enriquez-Sarano, M, Tajik, AJ, et al, J Am Coll Cardiol 1997; 30:746.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17054=[""].join("\n");
var outline_f16_41_17054=null;
var title_f16_41_17055="Organizing intrauterine hematoma";
var content_f16_41_17055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Organizing intrauterine hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior heterogeneous collection (delineated by + signs) in the lower uterine segment representing an organized clot measuring 7 x 12 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin R Chavez, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_41_17055=[""].join("\n");
var outline_f16_41_17055=null;
